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ABSTRACT 
More than 25% of all newly diagnosed breast cancer cases are ductal carcinoma 
in situ (DCIS), the most commonly diagnosed form of non-invasive breast cancer.  This 
incidence coupled with the detrimental side effects associate with traditional cancer 
treatment makes it critical to investigate the efficacy of alternative treatment regimens 
that are not as toxic to non-cancer cells.  The tumor-cytotoxic activities of secondary 
plant compounds including polyphenolics from mango (Mangifera indica L.) have 
previously been reported; however, the underlying mechanism, especially with DCIS 
breast cancer, has not been elucidated. 
In both an in vitro and an in vivo xenograft assessment of mango extract and 
pyrogallol (PG), a tannin-metabolite formed by bacteria in the gastrointestinal tract, had 
anti-proliferative activities in the DCIS cell line MCF10DCIS.com.  Reduced 
proliferation in vitro was attributed to a down-regulation of multiple constituents along 
the AKT/mTOR signaling axis. Within a low concentration of 10 mg/L both treatments 
significantly decreased total protein for mTOR and p-AKT and p-P70S6.  Neither 
treatment had significant interaction with 5-fluoro-uracil. 
In a xenograft model, the mango extract (0.8mg/day) and PG (0.2mg/day) 
significantly reduced tumor volumes by 50% over a 4 week exposure window where 
similar downregulation of the AKT/mTOR signaling axis was observed as in vitro, 
however, AMPK and p-AMPK at Thr172 were also upregulated. Sestrin, Becklin, and p-
ULK were all significantly elevated in tumor tissue by treatments.  Both treatments were 
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shown to cause elevated ROS production, which might have initiated the activation of 
AMPK.  In silico modeling demonstrated PG ability to directly bind with the allosteric 
site of AMPKα resulting in its activation.  PG treatment following siRNA knockdown to 
AMPK resulted in the rescue of total and p-AMPK levels in vitro.  This indicates that PG 
is not only involved in the activation of AMPK but also in the upregulation of its 
constituent expression, possibly by the downregulation of HDAC1, a suppressor of 
AMPK expression. An assessment of mouse plasma indicated that PG is rapidly 
metabolized into pyrogallol sulfate, likely by intestinal and hepatic sulfotransferases.  
Findings indicate that tannin-containing foods or PG may delay the development of 
DCIS breast cancer. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Incidence of Cancer 
It is estimated that 11 million new cases of cancer are diagnosed annually 
worldwide, with 7 million deaths being attributed to this disease [1, 2].  Therefore, 
cancer is estimated to cause mortality in more than 50% of those diagnosed; and 
therefore even small advancements in treatment could result in significantly increased 
survival and/or benefits to the quality of life for those suffering from it.  Asia has the 
greatest incidence, mortality, and 5-year prevalence of cancer (Figure 1). 
Figure 1. Breast cancer incidence, mortality, and prevalence for Africa, North 
America, Asia, Europe, Central/South America and Oceania [1].  
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Cancers that are gender-specific, for example, female breast and male prostate 
cancer, have the greatest incidence rates. If gender-specific cancers are eliminated from 
analysis, lung, stomach, colon, rectum, liver, in descending order, followed by cancer of 
the esophagus have the highest incidence worldwide. 
Table 1. Demographic of women diagnosed with DCIS [5]. 
Variable    n    Percent  
Age (years) 
<35 612 6.0 
35-44 5,219 10.9 
45-54 10.400 11.6 
55-64 9,366 9.5 
65-74 9,499 9.6 
75-84 5,188 7.7 
≥85 939 4.3 
SEER site 
San Francisco/Oakland 7,763 10.4 
Connecticut 6,381 9.0 
Detroit 7,341 9.6 
Hawaii 2,131 12.5 
Iowa 4,150 7.4 
New Mexico 1,663 0.8 
Seattle 6,040 9.9 
Utah 1,769 0.8 
Atlanta 3,796 11.6 
Race category 
White 34,490 9.2 
Black 3,306 10.2 
American Indian 82 7.3 
Asian/Pacific Islander 2,967 15.0 
Other 117 11.5 
Surgery 
BCS 21,394 54.5 
Mastectomy 17,687 45.5 
RT 11,630 26.2 
Of all newly diagnosed cancers, 1 out of 10 will be female breast cancer [3]. 
There is a relatively large variation of breast cancer incidence depending on 
geographical location, which is estimated to be greater than 10-fold. This range results 
from to multiple etiology including differences in hormonal, reproductive and nutritional 
factors [4]. Another contributing factor is soco-economic status; and societies that 
practice self-examinations and are able to diagnose breast cancer sooner. Self-
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examination techniques and mammography are associated with an increase in early 
diagnoses of breast cancer at the ductal carcinoma in situ stage, and this examination 
occurs with the greatest frequency among women of ages 35-54 (Table 1) [5].  Asian    
and Pacific Islanders are two of the least likely populations to be diagnosed due to 
limited access to medical resources.  
Hallmarks of Cancer 
 Cancer development is a multi-step cascade of events made up of 6 distinct 
stages (Figure 2) that include ongoing proliferation, desensitization to growth 
suppressors, invasion and metastasis, immortality and continuous replication, 
angiogenesis, and cell death resistance [2]. As of 2011, two additional stages have been 
proposed to be added to these traditional hallmarks of cancer, and these are 
reprogramming energy metabolism and evading immune destruction [6]. 
 
 
 
Figure 2. Schematic for the hallmarks of cancer [6].  
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Continuous Proliferation 
 In non-cancerous cells, cellular proliferation is a highly choreographed process 
controlled by multiple checkpoints that allow the cell to either move into mitosis or 
inhibit the cell cycle depending on the conditions. Cell division is generally classified 
into two different processes, 1) DNA duplication, and 2) the telophase portion of mitosis. 
These processes are regulated by specific proteins referred to as cyclin-dependent 
kinases, mostly classified as serine/threonine protein kinases [7]. Upon activation, these 
proteins cause a phosphorylation cascade specific to proteins responsible for cell cycle 
progression (Table 2) with nine major cyclins that navigate the mitotic cell cycle.  
 
Table 2. Cyclin-dependent kinases and their function related to cell cycle 
progression 
 
 
 
 
 
 
 
 
In cancer, this checks and balance system of cyclins and kinases is dysregulated 
due to genetic mutation or epigenetic modifications to either oncogenes or to tumor-
suppressor genes. Without functional checkpoints, cells continuously replicate resulting 
in hyperplasia in the absence of normal phases of cellular quiescence. In this process, 
cancer cells may become less dependent on exogenous growth factors and continue to 
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proliferate in their absence. Along with this, cancer cells are able to produce their own 
peptide growth factors and express an increased number of surface receptors that causes 
them to be more sensitive to lower concentrations of growth factors [8]. 
Desensitization to Growth Suppressors 
The cell cycle is regulated by anti-growth signaling pathways which maintain 
cells in a quiescence (G0) stage [9]. Surrounding cells can secrete factors that would 
normally cause a cell to halt proliferation, and cancer cells loose sensitivity to these 
factors.  One of the key tumor suppressor proteins associated with antiproliferative 
signaling is the retinoblastoma protein (Rb) [10].  This protein elicits its effect within the 
G1 phase. This phase is a critical point in the cell cycle and drives cells to either advance 
towards duplication or quiescence. Hyperphosphorylation of Rb (pRb) results in the loss 
of its antiproliferative activities. Upon hyperphosphorylation, pRb dissociates from the 
transcription factor E2F, which then allows E2F to enter the nucleus and begin gene 
transcription resulting in cell cycle progression and growth [11]. Common mutations in 
multiple types of cancer include the Rb gene [12]. 
Bypassing Apoptosis 
Not only are cancer cells able to desensitize themselves to growth-inhibitory 
signaling, but they are also able to avoid programmed cell death (apoptosis). Many 
different stimuli initiate apoptosis, including activation of the death receptor FAS  
(CD95 or APO-1) with a FAS ligand [13]. This process causes a cascade of signaling 
that normally causes an increase in mitochondrial ion permeability, resulting in the 
release of multiple constituents. DNA damage causes the upregulation of the tumor 
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suppressor protein p53 (P53) and the apoptotic promotor BAX [14]. When cytosolic 
levels of unphosphoralated BAX are increased, it interacts with Bcl-2 at the 
mitochondrial membrane and causes the release of cytochrome C, a critical apoptotic 
catalyst. P53 is commonly mutated in multiple cancer types, causing a loss of function 
either by genetic mutation or silencing via gene methylation. This results in 
phosphorylated BAX staying sequestered in the cytosol where it is unable to interact 
with Bcl-2 and prevent apoptosis [15]. 
Continuous Replication 
Non-cancerous cells have a proliferative limit allowing only a certain number of 
mitotic events to occur. Cancer cells lack this limitation [16]. Telomeres are repetitive 
nucleotide regions at the end of chromatids, that prevent degradation and typically 
shorten by 50-100 base pairs during the process of DNA replication [17]. The shorting is 
contributed to DNA polymerase not being able to fully replicate the 3 prime ends of the 
chromosome resulting in progressive shortening that will leave the chromosome ends 
unprotected, causing genomic instability and terminal fusions triggering cell death [18]. 
Telomerase-elongating enzyme is upregulated in cancer cells, preventing telomere 
shortening [19]. 
Prolonged Angiogenesis 
Tissues require blood flow to supply nutrients and promote gas exchange; and 
developing cancers trigger growth of new blood vessels. Vascular endothelial growth 
factor (VEGF) stimulates the proliferation of blood vessels in a process called 
angiogenesis. One main player in this process is thrombospodin 1 (TSP-1) an inhibitor 
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of tumorigenesis in healthy tissue [20]. TSP-1 is found in greater quantities in cells with 
wild-type p53. With certain mutations in p53, levels of TSP-1 drop significantly [21].   It 
is hypothesized that this downregulation of TSP-1 is responsible for an angiogenic 
phenotype rather then up-regulation pro-angiogenic genes. In studies where p53 was 
knocked out initially and reintroduced later, TSP-1 increased following the 
reintroduction of p53 and the angiogenic phenotype was lost [20]. 
Invasion and Metastasis 
 The metastatic stage of cancer is responsible for over 90% of deaths associated 
with this disease [22]. In this stage, tumor cells may separate and invade new locations 
in the body. The ability of cancer to metastasize is associated with several factors 
including adhesion proteins, like E-cadherin (E-cad).  E-cad has many critical functions, 
including interacting with catenins which link E-cad to the internal actin cytoskeleton 
(Figure 3) [23]. In this configuration, E-cad is not only responsible for intercellular  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Intra and extracellular E-cadherin cell adhesion [23]. 
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adhesion, but is also able to transduce transmembrane signaling regulating gene 
expression [24]. E-cad is lost in a majority of epithelium-derived cancers associated with 
genetic mutation, deletion, or hypermethylation along the promoter region. In general, 
downregulation of E-cad is associated with poor prognosis [25-27]. Mutation of other 
complex constituents, like α, β, and γ catenin also results in a loss of adhesion [28]. Also, 
upregulation of extracellular proteases cause degradation of stromal, blood vessels, and 
epithelial layers [29]. 
Breast Cancer 
Breast cancer includes a broad class of carcinomas affecting the mammary 
glands and tissue, and occurs in both female and male breast tissue. The breast is filled 
with 15-20 lobules, and these radiate around the areola (Figure 4). 
Figure 4. Anatomic features of the female breast [30]. 
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The lobules are the functional part of the breast responsible for lactation, which is 
triggered by hormonal signaling. The lobules are connected to ducts that lead to the 
areola, which is where milk is ejected from the breast. This internal structure is 
surrounded by adipose tissue [31]. 
There are multiple classifications for breast cancer, and the American Cancer 
Society categorizes them in the following way: 
Ductal Carcinoma In Situ (DCIS):  This is a form of pre-invasive breast cancer in which 
hyperplastic cells surround the ducts and are morphologically similar to cancer cells. It is 
believed that nearly all invasive breast cancers begin as DCIS [32]. DCIS progression is 
shown in Figure 5 along with critical genetic and epigenetic shifts which are believed to 
chaperone disease progression. 
Figure 5. Histological and genetic changes in the progression of DCIS 
invasive ductal carcinoma [32]. 
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There are multiple pathological features that differentiate DCIS from normal 
breast tissue including chromosomal imbalances.  It is estimated that as much as 70% of 
DCIS patients experience a loss of heterozygosity.  Furthermore, HER2 is overexpressed 
in almost half of DCIS cases while p53 is mutated 25% of the time in affected tissue [33, 
34].    DCIS shows similar molecular characteristics of invasive cancer without being 
malignant.  It is thought that a final set of events and alterations to both the DCIS and 
surrounding tissue causes the transformation into invasive cancer [35].  A high treatment 
success rate is associated with successful surgical removal of the tumor tissue.  It is 
estimated that 25% of newly reported breast cancer cases are classified as DCIS [36]. 
Clinically, this form of breast cancer has the highest occurrence and is estimated 
to represent 8 out of every 10 cases.  The site of origin is the milk duct.  This tissue goes 
through a proliferative remodeling process that is estrogen-dependent making this tissue 
vulnerable to excessive proliferation [37].  Invasion beyond the confinement of the duct 
into surrounding adipose tissue is the initiation of metastasis [38]. 
Invasive Lobular Carcinoma:  This form is very similar to that of invasive ductal 
carcinoma, except the origin of the pathology is the lobules instead of the milk duct [38].  
It too has the ability to metastasize and is estimated to be associated with 1 in 10 cases of 
breast cancer [39, 40]. 
There are additional, less common types of breast cancer such as inflammatory 
breast cancer, triple-negative breast cancer, Paget’s disease of the nipple, and phyllodes 
tumors [41-44]. 
11 
MCF10DCIS.COM Cell Line 
The model used in this study, is a MCF10DCIS.com cell line that is unique for its 
ability to form ductal carcinoma in situ-like tumors when xenographed into a nude 
mouse model.   This stage of cancer, DCIS, is common in 25%-30% of newly diagnosed 
breast cancer cases [45].  This cell line was more recently established as a model for 
early stage breast cancer [46].  The carcinoma in situ stage is a critical point in cancer 
development, because it is the last stage prior to metastasis.  At this stage, the growth 
may be surgically removed without the need for chemotherapy or radiation but beyond 
this stage requires a more aggressive treatment regimen. 
This cell line was established using premalignant immortalized breast epithelia 
variants from the MCF10AT cell line.  MCF10AT cells were xenographed into mice and 
resulted in lesions that were then used to start a cell culture colony, resulting in the 
MCF10DCIS.com cell line, characterized by its ability to form  rapidly growing lesions 
that are predominately DCIS [46] (Figure 6).  
Figure 6. Histologic appearance of MCF10DCIS xenograft in nude mice.  
A. is at day 36 of xenograph and passage 17, and B. is day 22 at passage 22 [46]. 
A B 
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DCIS.com cells have similar physical characteristics of naturally formed tumors.   
The dark areas in Figure 6A represent areas of necrosis which is common in a growing 
tumor when nutrients can no longer diffuse to those areas because of the increasing 
mass.  Tightly packed tubuli make up a majority of the tumor mass.  In Figure 6B, cells 
maintain both their nuclei and cell membranes.  Use of this cell line allows researchers 
to study breast cancer progression and provides a useful model to test novel 
chemotherapies and determine their efficacy in halting cell growth in this stage in vitro. 
Conventional Cancer Treatments 
The treatment of breast cancer is contingent on many factors, including the stage 
and the type of breast cancer.  Generally treatment regimens are divided into 6 different 
classes and include: targeted therapy, hormone therapy, radiation therapy, chemotherapy, 
sentinel lymph node biopsy, and surgery [47]. 
Targeted Therapy 
This treatment utilizes drugs or other compounds to specifically target cancer 
cells while minimizing effects to regular noncancerous cells.  Common treatments 
include the utilization of monoclonal antibodies, PARP inhibitors, anti-angiogenesis 
compounds, and tyrosine kinase inhibitors. 
Hormone Therapy 
Many types of breast cancer are hormone sensitive, therefore blocking or 
removing hormones, results in decreased cancer growth.  Both aromatase inhibitors and 
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tamoxifen are commonly used to treat estrogen-dependent neoplasia for early stage 
breast cancer. 
Radiation Therapy 
This therapy uses high-energy radiation to decrease cancer cell proliferation or 
decrease cancer cell viability.  There are two main ways to administer this treatment 
including external radiation with uses an external machine to emit radiation toward the 
cancer site.  The other method is internal radiation involving a radioactive compound 
that is directly administered via needles or catheters into or near the cancer site.  The 
high energy radiation damages the DNA of rapidly dividing cancer cells, causing 
mutations resulting in cell death.  The downside of radiation therapy is that normal cells 
are not excluded from the effects, resulting in side effects such as skin irritation, fatigue, 
and gastrointestinal irritation. 
Chemotherapy 
In this treatment, cancer-targeting drugs are either administered systemically or 
regionally in order to decrease cancer growth.  Administration is dependent on type and 
stage of cancer.  The main goal of this treatment is to either kill the cancer cells directly 
or halt their proliferation. 
Sentinel Lymph Node Biopsy  
In the progression of cancer, metastasis initiates at the lymph node responsible 
for lymphatic drainage from the tumor.  A screening utilizing a radioactive substrate or 
dye injected into the tumor determines if the lymph node was affected or not.  If the 
lymph node is found to have the dye or radioactive substrate present, then the lymph 
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node is removed.  Following this, a biopsy is done on the removed node to determine if 
cancer cells are present, and if cancer is present, additional nodes maybe removed. 
Surgery  
This is the most invasive treatment option which results in the removal of the 
tumor.  Two common forms of surgery include breast-conserving surgery and total 
mastectomy.  In breast-conserving surgery a lumpectomy can be performed, and consists 
of removing just the tumor itself, or a partial mastectomy, which removes some healthy 
tissue along with the tumor mass.  In a full mastectomy, the entire affected breast is 
removed, along with other tissue assumed to be affected including lymph nodes under 
the arm and chest muscle. 
Alternative and Adjunct Cancer Treatments 
Alternative cancer treatment methods are now becoming commonplace as 
adjunct treatment with traditional treatment regiments.  Both nutritional and naturopathic 
medicines are aiding in minimizing side effects and strengthening the immune system. 
Nutrition Therapy 
During cancer treatment, such as chemotherapy or radiation, a common side-
affect is gastrointestinal agitation resulting in weight loss and lack of nutritional uptake.  
In order for the body to have energy to help fight the cancer and increase treatment 
compliance among patients, altering the diet to maintain proper nutrition is critical.  
Maintaining ones weight during treatment with a well-rounded diet consisting of protein, 
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carbohydrates, fat, water, vitamins, and minerals also lowers the risk of infection, and 
expedites healing and recovery times. 
Naturopathic Therapy and Treatment 
This approach of treatment utilizes non-toxic and natural therapies to promote 
healing and increased quality of life.  The main goals are to reduce the side effects 
experienced from chemotherapy, to boost the immune system, and to mitigate pain.  
Following is a list of recommended treatments by the Cancer Treatment Centers of 
America: herbal and botanical preparations, acupuncture, hydrotherapy, physical therapy, 
dietary supplements, and homeopathic remedies. 
 
Polyphenol Production 
 A secondary plant compound is conventionally defined as an organic compound 
that is produced by the plant that is not required for growth, survival or nutrition.  These 
compounds aid as defense mechanisms for the plants that produce them [48].  
Polyphenols are the largest subset of secondary plant compounds and are produced in 
plants via the shikimate-phenylpropanoids-flavanoids pathway (Figure 7) with the main 
purpose of protecting the plant from multiple stresses including, heat, bacteria, viruses 
and mechanical damage [49].    Additionally, phenolic compounds give color and flavor 
to many fruits and vegetables [50].  Mangos are rich in mangiferin, gallotanins, the 
gallotanin penta-O-galloyl-glucoside, and methyl gallate [51-53]. 
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Figure 7. The shikimate-phenylpropanoids-flavanoids pathway 
 
 
Mango Fruit (Mangifera indica L.) 
Mango is one of the most cultivated tropical fruit crops in the world and ranks 
number 5 in production with the other four being bananas, pineapple, papaya, and 
avocado [54].  While the pulp is the most readily consumed part of the mango, beneficial 
health properties have also been attributed to both their peel and seed.   Mangos are 
known for their high levels of vitamin C, β-carotene, and minerals (Table 3).   It is 
believed that this fruit was first grown in Asia over 5,000 years ago.  At one time this 
fruit was considered exotic, but now it is commonly grown in both North and South 
America.  Over half of the world production of all mangos takes place in India and make 
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Table 3. Nutrient values in 100g Mango Pulp 
up its primary fruit crop.  The four other large mango producing countries are China, 
Thailand, Mexico, and Indonesia [55, 56].  Due to strict USDA import restrictions in the 
US, the US market predominantly carries Haden, Tommy Atkins, Kent, and Keith 
varieties [57].  
Every part of the mango including the skin, seed and bark of the tree have been 
used in ancient medicines for a variety of different ailments [58].  Currently 
hypothesized medicinal uses for mango fruit include reduction or prevention of macular 
degeneration, multiple gastrointestinal (GI) disorders including Crohn’s Disease, 
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ulcerative colitis and colon cancer, improving general GI health including digestion, and 
even improving bone health [59]. 
Anti-proliferative and Preventive Activities of Polyphenols in Cancer 
Several studies report the anti-proliferative activities of polyphenols.  Resveratrol 
is a heavily studied polyphenol found in grapes and has shown to have antiproliferative 
effects in colon, breast, and prostate cancer [60-62].  Another highly published 
polyphenol EGCG, found in green tea, has been implicated to impede melanoma, 
hepatocellular carcinoma, and colon cancer proliferation as just some of its beneficial 
health properties [63, 64]. 
Pyrogallol 
A unique characteristic of mango is the level of gallic acid it contains.  
Unfortunately, gallic acid has poor bioavailability systemically, which could be due to 
the fact it is quickly metabolized or because of its polar characteristics [65, 66].  
Following gallic acid consumption, gut microbiota metabolize gallic acid into pyrogallol 
(Figure 8) [67].  It is this conversion by tannase producing bacteria which is 
hypothesized to potentially increase the bioavailability of gallic acid and pyrogallol [68].   
Pyrogallol has been examined for its health benefits in multiple disease models, and has 
been done so as a single compound, or as a pyrogallol-type structure attached to other 
compounds.  One study that focuses on tea catechins concluded that catechins that had a 
pyrogallol in a β-ring had a structural activity relationship with causing apoptosis in 
cancer cell lines [69].  When histiocytic lymphoma cells were exposed to pyrogallol 
containing catechins there was a significant induction in caspases, which are enzymes 
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with an essential role in apoptosis, while catechins that did not contain pyrogallol did not 
induce apoptosis.  Another study that focused on free radical scavenging ability 
concluded that flavonoids containing pyrogallol were more efficient in scavenging toxic 
superoxide anion radicals than flavonoids that did not have the pyrogallol moiety [55]. 
These radicals are toxic in many biological systems and contribute to pathogenesis in 
many diseases. 
 
 
 
 
 
 
Figure 8. Chemical structure of pyrogallol 
 
 
 
Analysis of the binding affinity of pyrogallol-based molecules, demonstrated 
pyrogallol’s affinity for Bcl-2 protein [70].  In that experiment, different pyrogallol-
based compounds were modeled with Bcl-2, and results indicated that the hydroxyl 
groups form hydrogen bounds with R146 and N143 in the BH3 binding grove of Bcl-2 
[71].  This binding promoted apoptosis by acting as an antagonist and decreasing the 
ability of Bcl-2 to bind with pro-apoptotic constituents like Bad, Bax, Bim, and Bid. 
Some conflicting evidence describes pyrogallol as an O2
− generating compound 
which results in cell death [72].   It has been a concern that antioxidants in high 
concentrations may become pro-oxidants [73].   
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While the body has its own defense mechanisms against reactive oxygen species 
(ROS) that include superoxide dismutase, glutathione, catalase, glutathione peroxidase, 
ingested exogenous antioxidants such as polyphenols, vitamin C & E, and carotenoids 
are also able to quench ROS and prevent their negative effects [74].  The problem arises 
at high concentrations of exogenous antioxidants.  Firstly, a pro-oxidative effect can 
occur at elevated concentrations, and secondly a certain level of ROS is required for 
some cell signaling pathways, and therefore eliminating all ROS is not a suitable 
solution for disease prevention [75].  As with most compounds, a proper dose is required 
to obtain the desired effect without enduring toxic effect associated with elevated 
concentrations.   
Pyrogallol also has health benefits as a mono-therapy.  In one study, pyrogallol 
was able to halt cell cycle progression of lung cancer cells in G2-M phase while showing 
less toxic effects in non-cancerous bronchial epithelial cells in vitro [76].  These effects 
were attributed to decreased B1 and Cdc25c, both of which are cell cycle proteins, and 
increased phosphorylated levels of Cdc2 in as little as 4 h post treatment.  This study 
also demonstrated that pyrogallol was able to upregulate key constituents along the 
apoptotic pathway, including up-regulating protein levels of poly (ADP)-ribose 
polymerase (PARP) and BAX, along with decreased levels of Bcl-2.  These results were 
also demonstrated in a nude mouse xenograph model, and animals that were treated with 
75 µg/kg/day pyrogallol  for 5 weeks had decreased tumor sizes compared to PBS 
treated control animals [77]. 
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While pyrogallol has been implicated to have therapeutic benefits in certain 
disease states, the data base for toxicological assessment is less robust.  Pyrogallol has 
been used in a variety of commercial applications which includes being used in the 
development of photography and holography, along with being an ingredient in both hair 
and wood dyes [78-80].  The industrial application of pyrogallol causes concern for 
potential occupational exposure.  Besides the occupational route of exposure, pyrogallol 
exposure could occur following the consumption of tea and smoked meats [81, 82].  
Along with this, inhalation exposure to pyrogallol occurs during the smoking of tobacco 
products [83].  
Table 4. Acute oral LD50 for pyrogallol in four different species [77]. 
Reports have previously shown that acute oral consumption of elevated levels of 
pyrogallol can result in renal injury, gastrointestinal tract irritation, methemoglobinemia 
which decreases the binding affinity of oxygen to hemoglobin, and even death in 
extreme circumstances [77].  Table 4 lists the acute oral LD50 for various species. 
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Gallic Acid  
Gallic acid or 3,4,5-trihydroxylbenzoic acid, is naturally found in fruits, red 
wine, and green tea (Figure 9).  A unique characteristic about mangos is that gallic acid 
is the major polyphenol present [59] and one reason this compound is commonly 
examined when discussing the  beneficial health properties associate with mango 
consumption.  Gallic acid has been implicated as having beneficial anti-inflammatory, 
cancer preventing, and anti-microbial properties.  When examining effects of these 
compounds on breast cancer, it was demonstrated that gallic acid is able to affect 
multiple factors associated with cancer progression.  Gallic acid was tested in MCF-7 
breast cancer cells, and significantly reduced cellular proliferation by 42% compared to 
controls at concentrations as low as 5 µg/mL [84].  This compound also caused    
 
 
 
 
 
 
Figure 9. Chemical structure of gallic acid. 
 
 
 
significantly induced G2/M phase arrest in this cell line at concentrations ranging from 
2-12 µg/mL.  Western blots were done in order to determine which constituents of the 
cell cycle were being altered, and protein levels of cyclin A, CDK2, cyclin B1 and 
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CDC2/CDK1 were all decreased in a dose-dependent manner.   Further investigation 
revealed diminished levels of Skp2, which is a member of the SCF-type E3 ligase.  Skp2 
has many functions, which include the ability to ubiquitinate various cancer proteins, 
including p27Kip1, p21Cip1, p57Kip2, and c-Myc. 
Gallic acid, besides being present in numerous food stuffs, is also present in 
paint, color developers, ink, and pharmaceuticals [85].  With multiple routes of exposure 
to humans, it is important to examine some of the adverse effects that could results from 
gallic acid exposure at elevated levels. One study that used F344 rats that were exposed 
to 0, 0.2, 0.6, 1.7 and 5% gallic acid for 13 weeks revealed that animals that received 5% 
gallic acid had reduced body weights throughout the duration of the study when food 
consumption was equal across all groups [86].  It was concluded the gallic acid, like 
tannins, may bind with essential proteins causing them to precipitate, therefore reducing 
their ability to be absorbed along the gastrointestinal tract [87].  It was also concluded 
that gallic acid may inhibit some essential digestive enzymes such as trypsin, α-amylase, 
and lipase [88].   
Underlying Mechanisms of Action of Polyphenols  
Antioxidant and Free Radical Scavenging Activities 
  A majority of the health related effects associated with polyphenols are 
attributed to their antioxidant activities associated with their phenolic ring structures.  All 
polyphenols contain aromatic rings with hydroxyl groups.  The hydroxyl group is able to 
donate a hydrogen atom to quench a free radical.  The remaining positive charge is then 
displaced amongst the aromatic ring [89].   Many health conditions are associated with 
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damaged caused from free radicals, therefore reducing radicals is advantageous.  In 
various in vitro studies, it has been shown that mango polyphenols are able to prevent 
DNA damage caused by oxidative stress in various cell lines [90].  Along with their 
antioxidant activity,  multiple polyphenols have demonstrated the ability to form 
complexes with multiple metal ions, such as iron, vanadium, manganese, aluminum, and 
calcium [91].  Iron for example binds  polyphenols which could prevent it from forming 
additional radicals by interrupting the Fenton reaction [92]. 
Protein Binding 
 Polyphenols have an affinity for proteins, and form soluble complexes.  It is 
believed that each polyphenol has a fixed number of binding ends that are able to bind 
with a limited number of protein binding sites [93].  When there is a greater quantity of 
protein present compared to polyphenols, the interaction between the two causes 
bridging between two different proteins molecules resulting in protein dimers and small 
aggregates.  When this ratio is reversed and there are more polyphenols present than 
protein, binding between two proteins via a polyphenol is less likely.  The binding 
potential of the two is also both temperature and pH dependent.  It has also been 
concluded that proline-rich proteins had the highest affinity for polyphenols [94].  The 
affinity of these compounds for proteins could impact multiple biological processes 
including enzyme function.  
PI3K Signaling and Activation of AKT 
 Phosphoinositide 3-kinase (PI3Ks) are a group of lipid kinases responsible for 
signaling that promote growth, cell survival, glucose homeostasis, and metabolism that 
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are dysregulated in many cancer types [95].  Upon extracellular activation by FGF 
(fibroblast growth factor), VEGF (vascular endothelial cell growth factor), HGF (human 
growth factor), Ang1 (angiopoietin I), or insulin to receptor tyrosine kinase (RTK) 
causes autophosphoryalation of PI3K.  Currently there are three different classes of 
PI3K; and Class 1 PI3K will be the focus here (Figure 10).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. PI3K signaling and activation of AKT.  
 
 
  
 PI3K is a heterodimer which contains a catalytic and regulatory subunit.  SH2 
and SH3 domains make up the regulatory subunit and p110α, β, δ, γ are the four different 
catalytic subunits.  When activated by insulin, insulin receptor substrate (IRS) is required 
for proper PI3K binding and, when activated by integrins, focal adhesion kinase (FAK) 
is required as an upstream regulator. Following this, PI3K phosphorylates the 3’-OH 
group on phosphoinositides (PI), a lipid present on the membrane.  This activation of 
P13K by the receptor causes the phosphorylation of multiple PIs with the primary 
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conversion being PIP2 to PIP3 in cancer.   This phosphorylation results in AKT 
mobilization to the phospholipid membrane which leads to its activation.  AKT is 
phosphorylated on two distinct sites, Thr 308 by PDK1, and Ser 473.  The Ser 473 
phosphorylation has been hypothesized to occur by multiple factors, including mTOR, 
however, a definitive activator of this phosphorylation site has yet to be determined. 
mTOR Pathway 
A main phenotypical response following polyphenol exposure in vitro is 
decreased cellular proliferation.  Due to this response a major cell signaling pathway of 
interest is the mammalian target of rapamycin (mTOR).  This pathway is important for 
multiple cell functions which include protein synthesis and lipid biogenesis, cell cycle 
progression, proliferation, and inhibition of autophagy.  mTOR is normally subdivided 
into two main complexes, which include mTORC1 and mTORC2 (Figure 11), and each 
responds to a variety of stimuli such as oxygen, amino acids, genotoxic stress, energy 
Figure 11. Protein composition for mTORC1 and mTORC2 [96]. 
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status, growth factors and nutrients.  These two complexes have two different protein 
compositions, and the reason they are both initiated by different factors and control 
different biological processes.  The proteins along with their functions are summarized 
in Table 5. 
Autophagy and Programmed Cell Death 
Autophagy, along with apoptosis and necrosis, is a type of programmed cell 
death (PCD) [97].  PCD is a critical cellular function that balances cell survival with 
death; and an imbalance in this process can result in either cells becoming resistant to 
death stimuli or decreased viability.  Apoptosis is characterized by specific biochemical 
processes along with alterations in morphology.  A cell undergoing apoptosis will have a 
unique phenotype including condensed and fragmented nucleus, blebbing of the cellular 
membrane, and an overall reduction in cell size [98].   Necrosis is another type of 
Table 5. Individual proteins with their function that make up mTORC1 and 
mTORC2  
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programmed cell death which exhibits organelle dysfunction, cellular enlargement, and 
cell lysis.  There are many key biochemical signaling components that are associated 
with autophagy and these are outlined in Figure (12). 
 Autophagy is a catabolic process that utilizes autophagosomes which are double 
membrane vesicles that engulf unwanted cytoplasmic contents.  Following the 
encapsulation of material the autophagosome binds with a lysosome/vacuole which leads 
to the degradation of the unwanted material [99].  Autophagy occurs at housekeeping 
levels under normal conditions, but upregulated during times of stress which include 
nutrient deprivation [100]. Dysregulation of this process has been associate with cancer 
progression, cardiovascular disease, and both neurodegenerative and metabolic disorders 
[101].  In humans Atg1 (also known as ULK1 and ULK2), Atg13, and FIP200 form a 
 complex which results in autophagy [102].  This complex formation can be inhibited by 
hyper-phosphorylation of Atg13 from mTORC1 [103].  When this occurs Atg13 is no 
longer able to bind with Atg1. 
 
 
 
 
 
 
 
 
 
 
Figure 12. Summary of AMPK Signaling [104]  
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5-Fluorouracil (5-FU) 
The widely used cancer drug, 5-FU, has been used for over 40 years in multiple 
cancer types, including breast cancer, all gastrointestinal cancers, bladder cancer, and 
both head and neck cancers [105].  This compound is considered an antimetabolite 
which causes dysregulation of various essential biosynthetic processes including 
inhibition of thymidylate synthase (TS) [106].  TS is an enzyme responsible for the 
conversion of deoxyuridine monophosphate to deoxythymidine monophosphate, which 
is a constituent required for thymine formation.  Thymine is one of the four nucleobases 
constituents that comprise DNA [107].  When the TS enzyme is inhibited it causes 
increased levels of deoxyuridine monophosphate and decreased levels of 
deoxythymidine monophosphate, resulting in DNA damage.  5-FU is also able to 
incorporate itself into both DNA and RNA, which causes dyregulation with protein 
translation.  5-FU enters the cell via facilitate diffusion and readily incorporates into 
these macromolecules as a uracil [108].  Figures 13 depicts the metabolism and 
mechanism of action for 5-FU. 
5-FU treatment has multiple drawbacks including developing drug resistance and 
a plethora of side effects including cardiotoxicity, alopecia, maculopapular eruption, 
nausea, diarrhea, vomiting, mood disorders, and neurological damage [109].  Due to the 
multiple toxicological effects of 5-FU treatment, additional research needs to be 
conducted in order to maximize the benefits of 5-FU with mitigating the deleterious side 
effects.  It is hypothesized that co-administration of 5-FU with natural compounds, such 
as polyphenols may reduce the efficacious dose of 5-FU therefore reducing the side 
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effects or preventing drug resistance.   One example of this is with curcuminoids which 
were found to reduced 5-FU resistance in colon cancer cells by suppressing the 
multidrug resistance gene [110]. 
Figure 13. 5-FU metabolism and mechanism of action [122]. 
Polyphenols are estimated to be ingested at gram levels in the western diet and 
have been shown to affect (CYP) cytochrome P450, and therefore it is rational to 
conclude that they could have drug interactions [111].  CYP3A4, an abundant liver 
enzyme believed to be responsible for metabolizing more than 50% of prescribed drugs, 
and CYP2C9, another major drug metabolizing liver enzyme, activities were examined 
following exposure to a panel of over 60 different polyphenols [112].  The polyphenols 
tested included flavanones, chalcones, isoflavones, coumarins, flavan-3-ols, flavones, 
and other closely related compounds.  They were tested at a concentration of 100 µM.  A 
summary of the results can be seen in Figure 14. 
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Figure 14. Inhibitory effects of polyphenols on selected p450 enzymes. 
CYP3A4-catalyzed TST 6β-hydroxylation (black background) and CYP2C-catalyzed 
DIC 4’-hydroxylation (white background) [112]. 
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In summary, most of the flavones, flavonols and coumarins investigated caused 
greater than an 80% inhibition of either CYP3A4 or CYP2C, while flavones, 
isoflavones, flavan-3-ols, and chalcones exhibited weaker inhibition that was less than 
50%.  Conclusively, these compounds could alter a drug’s metabolism and could also 
affect the mode in which a drug is absorbed, distributed, and eliminated. 
Besides affecting CYP activity, polyphenols also affect transporters.  These 
transporters are responsible for multiple biological processes including the efflux of 
chemicals from intestinal cells.  These transporters include multidrug resistance proteins, 
including P-gycoprotein among others, and are a principal factor for drug absorption 
along the gastrointestinal (GI) tract.  Table 6 lists intestinal ATP binding cassette 
transporters (ABC transporters) and their physiological function. 
As can be seen in the table, polyphenols have the ability to alter the absorption of 
many different compounds, and therefore the concern for food-drug interaction needs to 
be examined further in both in vitro and in vivo models.  One objective in this research is 
to examine if mango polyphenols modulate the effects of 5-FU.  5-FU also has utility as 
a positive control allowing for comparisons to be made between polyphenol treatment 
and a widely used conventional cancer therapy. 
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Table 6.  Intestinal ABC transporters and their physiological function. 
Hypothesis 
The overall hypothesis of this research is mango polyphenols and mango derived 
metabolites may have anti-cancer effects on in situ breast cancer through inhibition of 
proliferation.  Polyphenols may delay breast cancer progression through suppressing 
proliferation by modulating the IGFR-1-AKT-AMPK-mTOR-signaling axis.  The 
downregulation of mTOR could be directly caused through the activation of AMPK. 
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Objectives 
1) Investigate the cytotoxic and anti-proliferative activities of mango polyphenols
and pyrogallol in cultured MCF10DSCIS.com cells with the IGFR-1-AKT-mTOR 
signaling axis being of primary interest.  Possible food/drug interaction between 
polyphenols from mango and the widely used cancer drug 5-FU will also be investigated 
for possible additive or synergistic effects from joint treatment. 
2) Investigate if the anti-proliferative effects of mango polyphenols that occur in
vitro translate to an in vivo xerograph model.  Mice will orally receive a mango extract 
or pyrogallol at physiologically relevant doses to determine their effects on tumor 
growth.  Tumors will undergo a mechanistic evaluation to determine if the 
AKT/mTOR/AMPK is being modified.  ROS production will also be a major focus 
because of its ability to initiate AMPK signaling.  In silico modeling of AMPK will also 
be conducted to determine if the structure of pyrogallol could cause direct activation. 
3) To further investigate the mechanism associated with the anti-proliferative effects
of pyrogallol in vivo, and to verify results.  Escalated doses will be used in order to 
determine if toxicity manifests. The bioavailability of pyrogallol and associated 
metabolites will be examined in tumor tissue and in plasma. 
5) Determine if pyrogallol has the ability to cause epigenetic modification as it
relates to HDAC1 inhibition.  
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CHAPTER II 
MANGO POLYPHENOLICS REDUCE PROLIFERATIOIN OF DCIS BREAST 
CANCER IN VITRO- POTENTIAL INVOLVEMENT OF THE IGFR-1-AKT-MTOR 
SIGNALING AXIS AND POSSIBLE FOOD/DRUG INTERACTIONS WITH 5-FU 
Summary 
In situ breast cancer is a late stage cancer, and intervention during this stage of 
tumor progression may prevent metastasis.  In this study, we elucidated the molecular 
mechanism underlying the anti-proliferative activities of a low molecular weight fraction 
of mango (Mangifera indica L.) polyphenols (ML) in an in situ breast cancer cell line, 
MCF10DCIS.COM.  This line was selected due to its ability to form DCIS lesions in 
vivo which includes the formation of a myoepithelial layer, and is a validated model for 
studying DCIS therapeutics.  Mangos are rich in large gallotannin moieties but also 
contain low molecular weight gallic acid derivatives.  In contrast to gallotannins, low 
molecular size polyphenols are hypothesized to have a greater prospect of crossing 
phospholipid membranes and being bioactive intracellularly.  Gallotannins themselves 
are not intestinally absorbed through the intestinal lumen but yield metabolites upon 
digestion by the intestinal microflora.  Pyrogallol (PG), a central microbial gallotannin-
metabolite, was therefore included in this investigation because of its bioavailability and 
relevance as a physiological metabolite. The objective of this study was to investigate 
the anti-proliferative activities of ML and PG and to identify pathways involved 
including the PI3k/AKT/mTOR signaling axis in MCF10DCIS.COM.  Fluorouracil (5-
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FU), a widely used genotoxic cancer therapeutic, was used a positive control and in 
combination with ML and PG to assess potential interactions.  Non-cancer mammary 
fibroblasts (MCF-12F) were treated with ML and PG and non-cytotoxic dietary relevant 
concentrations were selected for the investigation in MCF10DCIS.COM cancer cells. In 
addition to proliferation and viability, mRNA and expression of total and phosphorylated 
protein were investigated.  Both, ML and PG significantly reduced proliferation in 
MCF10DCIS.COM, but did not significantly reduce viability following a 48h exposure.  
ML significantly reduced mRNA expression of AKT and mTOR while PG significantly 
reduced mRNA of HIFα, AKT, mTOR and IGF1-R.  LF and PG reduced protein 
expression of IGF1-R, IRS1, IF, AKT, and P70S6.  In addition, PG reduced mTOR 
protein.  Both treatments also had an effect on phosphorylated protein levels, with PG 
significantly reducing IGF1-R, AKT, and P70S6 levels. ML had a similar effect and 
significantly decreased IR, AKT, and P70S6 phosphorylation levels.  Within the low 
concentration-range, ML and PG did not interact with the cytotoxic activities of 5-FU. 
Overall, the PI3k/AKT/mTOR signaling axis appears to be implicated as causal in 
decreased proliferation induced by diet-relevant concentrations of MG and PG. 
Introduction 
It is estimated that 1 in 8 women will be diagnosed with breast cancer in their 
lifetime, and this incidence is the highest among cancers affecting women [113].  Breast 
cancer is a multi-factorial disease with several stages, and ductal carcinoma in situ 
represents stage 0.  This stage is pre-invasive and characterized by clonal proliferation of 
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cells that accumulate within the lumina of the mammary duct.  Essentially, all invasive 
breast cancers arise from this stage [32].  Therefore, preventing the progression of this 
stage or decreasing proliferation of these cells may prevent metastasis.  The development 
of this cancer can be dependent on multiple risk factors, which include genetic 
susceptibility, family history, age, lifestyles, and breast tissue composition [114-116].  
Considering the increased safety profiles of naturally derived polyphenol 
compounds compared to synthetic small molecule chemotherapeutics, natural 
compounds may have utility as a standalone treatment or as adjuvant therapy [90].  
Multiple health benefits including cancer-cytotoxic properties have been ascribed to 
polyphenolics, but their intestinal microbial metabolites have not frequently been 
investigated [117-121].  
Mangos (Mangifera indica L.) are rich in gallotannins and lower molecular 
gallates including gallic acid[122].  Gallic acid is known for its cancer-cytotoxic 
activities that has been investigated in vitro and in vivo [90, 123].  Pyrogallol, which is 
produced as a metabolite by the gut microflora following consumption of mango, also 
has been found to be anti-carcinogenic, although the molecular mechanism has not been 
intensively investigated [68].    
The PI3K/mTOR/AKT axis plays a critical role in multiple cellular functions, 
including proliferation, metabolism, survival, migration and angiogenesis. This signaling 
axis is frequently dysfunctional in cancer cells resulting in ongoing proliferation [124].  
The mTOR pathway can be regulated through intracellular or extracellular stimuli [96, 
125].  Polyphenols have previously been demonstrated to downregulate the mTOR 
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pathway and therefore it is hypothesized that this pathway is involved in the mechanism 
[126-129]. 
The objective of this study was to examine the cancer cytotoxic activities of 
mango gallates and pyrogallol on in situ breast cancer cells in vitro.  Additionally, the 
interactions of these natural compounds with 5-fluorouracil (5-FU), a common cancer 
drug that has been used clinically for more than 40 years, was investigated.  5-FU causes 
dysregulation of various essential biosynthetic processes, including thymidylate synthase 
[106].  Also, 5FU is able to incorporate into macromolecules such as DNA and RNA and 
cause downstream deficiencies in protein translation.  In the current study, 5-FU was 
included as a positive control when administered independently and to determine if there 
were any interactions with the gallates or pyrogallol when co-administered. 
LF mango extract was investigated as a source of multiple structures of gallates 
and pyrogallol was of interest as the major microbial metabolite of gallotannins and in 
previous preliminary studies it had the highest anti-proliferative activities in cancer cells 
compared to other gallate compounds.  
Materials and Methods 
Extractions and Chemical Analysis 
ML was fractionated from a complete polyphenolic extract as previously reported 
with slight modifications [130].  In brief, the mesocarp of mangoes was homogenized 
and polyphenols were extracted with 1:1 Methanol: Acetone for 30 minutes. Insoluble 
solids underwent three serial extractions.  Solvents were evaporated with a Buchi RII 
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Rotavap (Waltham, MA) at 45°C. Polyphenols were concentrated using C18 solid-phase 
extraction.  The C18 column removed all polar reducing agents including reducing 
sugars and ascorbic acid.  To retain water-soluble phenolics that did not bind to C18, the 
unbound fraction was extracted in 1:1 ethyl actate:water. After evaporation of solvents, 
tannins were removed by filtering the crude extract through Sephadex LH-20.   After 
solvent evaporation, total phenolics were measured spectrophotometrically using the 
Folin-Ciocalteu assay with values expressed as mg gallic acid equivalents (GAE)/L.  
Individual polyphenolics were identified using C18 reverse phase chromatography on a 
Waters Alliance 2690 HPLC-PDA system (Milford, MA).  Characterization and 
quantification of individual polyphenolics was accomplished by HPLC-MS Thermo 
Finnigan Surveyor HPLC-PDA coupled to a Thermo Finnigan LCQ Deca XP Max MSn 
ion trap mass spectrometer equipped with an ESI ion source (Thermo Fisher, San Jose, 
CA). Briefly, gradient separations were performed using a Phenomenex Kinetex C18 
column (150 × 4.6 mm, 2.6 μm) at room temperature. Injections were made into the 
column by use of a 25 μL sample loop. Mobile phase A was 0.1% formic acid in water, 
and mobile phase B was 0.1% formic acid in methanol run at 0.45 mL/min. A gradient 
was run of 0% phase B for 2 min and changed to 10% phase B at 4 min and held to 10 
min, from 10 to 40% phase B in 25 min, from 40 to 65% phase B in 35 min, and from 65 
to 85% phase B in 41 min and held to 50 min before returning to initial conditions. The 
electrospray interface worked in negative ionization mode. Source and capillary 
temperatures were set at 275°C, source voltage was 4.00 kV, capillary voltage was set at 
−42 V, and collision energy for MS/MS analysis was set at 35 eV. The instrument 
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operated with sheath gas and auxiliary gas (N2) flow rates set at 20 and 10units/min, 
respectively. 
Cell Culture 
 Human breast cancer cell line MCF10DCIS.COM were obtained from Asterand, 
Inc. (Detroit, MI) and cultured in DMEM-F12 media from (Invitrogen. Carlsbad, CA) 
supplemented with 10% horse serum from (Atlanta Biologicals, Lawrenceville, GA). 
The non-cancerous breast epithelial line MCF-12F was purchased from ATCC 
(Manassas, VA) and maintained per the vendor’s recommendations.   Cells for the 
proliferation and viability assay were seeded at a density of 15,000 cells/well in a 24-
well plate and allowed to attach overnight.   Following attachment, cells were treated in 
2% FBS media for 24 h with ML or PG at 1-10 mg GAE/L (7.93-79.3µM) for cancer 
cells and 1-100 mg GAE/L (7.93-793µM) for non-cancer cells.  The stock solutions were 
prepared as 5000 mg/L polyphenols in 25% DMSO.  The final DMSO concentration was 
0.1% (1µl in 1 ml), and the uniform concentration was treated to control and treatment 
groups.  5-FU was used as a positive control at 0.5 mg/L (3.85 µM), and the same 
concentration was used for co-incubations with ML or PG for 24 h. After 24 h, cells 
were detached using trypsin EDTA at 0.25%. Proliferation and viability were assessed 
using a Muse Cytometer from Millipore (Billerica, MA).  We performed cell 
proliferation assay with the objective of selecting the relevant dose-range that does not 
induce cytotoxic activities in normal cells but cytotoxic effects in the breast cancer cells. 
ML was investigated as a source of multiple structures of gallates, and PG was of 
interest as the major microbial metabolite of gallotannins. The selected 5FU-
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concentration caused low cytotoxicity in cancer cells in order to detect any possible 
synergistic activities of ML and PG. 
Analysis of mRNA Expression by RT-PCR 
 mRNA analysis was performed as previously described [131], using the Qiagen 
RNA isolation kit (Valencia, CA) according to the manufacturer’s protocol after 12 h of 
treatment with ML or PG.  Cells were seeded at 100,000 cells/well in a 12 well plate for 
24 h, and treated in either ML or PG at 1-10 mg GAE/L for 24 h. mRNA was extracted 
from treated cells, and cDNA was synthesized from the isolated RNA with the use of a 
Reverse Transcription Kit (Invitrogen Corp., Grand Island, NY). Primers were designed 
using the Primer Express Software Version 3. (Applied Biosystems, Foster City, CA) and 
purchased from Integrated DNA Technologies Inc. (Coralville, IA). qRT-PCR was 
conducted on an ABI Prism 7900 Sequence Detection System (Applied Biosystems, 
Foster City, CA) using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, 
CA). 
Multiplex Bead Assay 
 MCF10DCIS.COM cells were seeded at 200,000 cells/well in a six well plate 
and allowed to attach overnight. Cells were treated with ML or PG at 1-10 mg GAE/L 
for 24 h. Protein was extracted (25 µg) from tumor cells and prepared to determine total 
and phosphorylated protein levels of key components of the mTOR pathway utilizing 
multiplex kits and protocols (Millipore, Billerica, MA). Analysis was performed using a 
Luminex L200 (Luminex, Austin, TX). Data was analyzed using Luminex xPONENT 
Version 3.1. 
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Statistical Analyses 
Quantitative data represent the means ± SE. Data was analyzed by one-way 
analysis of variance using JMP 10 (SAS Institute Inc., Cary, NC). Tukey’s HSD was 
used (p<0.05) to determine statistical differences between treatment groups. 
Results 
Chemical Analysis 
Utilizing HPLC-MS analysis, polyphenols were identified in the mango extract 
(Fig. 15A). Four major compounds were identified (Fig. 15B) including, mono-galloyl 
glucoside (Peak 1 and 3), gallic acid (Peak 2), and hydroxybenzoic acid hexoside (Peak 
4) (Fig. 15B). Fig 15C is the chemical structure of pyrogallol.  The concentration of total
phenolics was quantified using the Folins Ciocalteu assay as 1174 mg/L GAE.  
Cell Cycle Kinetics 
Previous studies have indicated that anti-proliferative polyphenols may arrest cell 
cycle in different stages [132-134].  In this study, PG did not significantly alter cell cycle 
kinetics following 12h exposure. ML caused a minor arrest in the S-phase (data not 
shown).  The absence of effect in the PG treatment may be attributed to the low 
concentration used or the treatment requiring a longer exposure window. 
Anti-proliferative Effects of Mango Polyphenols and Pyrogallol in MCF10DCIS.COM 
In a preliminary screen, the anti-proliferative activities of selected polyphenolic 
compounds and their metabolites were evaluated in MCF10DCIS.COM cells at 1 mg/L 
for 48 h (Fig. 16A).  The greatest anti-proliferative activities were observed in cells 
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Figure 15. Characterization of compounds in mango polyphenols.  
A) Representative chromatogram at 280 nm of the low molecular weight mango 
polyphenol fraction, B) tentative structures for compounds 1-4: Peak 1 and 3 
monogalloyl glucoside, Peak 2 gallic acid, Peak 4 p-hydroxybenzoic acid hexoside,21 C) 
chemical structure for pyrogallol. 
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treated with ML and PG decreasing proliferation greater than 55% and 50%, 
respectively. For this reason, these two treatments, ML and PG, were selected for 
additional analyses. 
In previous studies, synergistic interactions between polyphenols and 
conventional cancer treatment drugs were observed, including 5-FU [110, 135].  5-FU 
treatment was included to act as a positive control, and to evaluate if a combinational 
treatment with both polyphenol treatments could produce additive or synergistic effects. 
These results are presented as paired bars to compare the effect of ML or PG treatment 
individually and in combination with 5-FU. In this study, cells were pretreated with PG 
and ML at 10 mg/L for 24 h followed by a treatment with 5-FU at 0.5 mg/L for an 
additional 24 h (Fig. 16B). Both, ML and PG at a relevant dietary dose of 10 mg/L, 
significantly reduced cellular proliferation by 34% and 25%, respectively, compared to 
the control.  These treatments did not reduce proliferation to the levels seen in a 
treatment of 48 h at 1 mg/ml because the exposure window was reduced by half.  A 
longer exposure window in the initial screen was done in order to determine if the 
compounds have an anti-proliferative effect even at lower concentrations. The 10 mg/L 
concentration was selected because it is relevant to dietary intake from foods and dietary 
supplements.  Viability was assessed in the non-cancer cell line MCF-12F for 48 h, 
where ML and PG decreased viability at concentrations of 25 mg/L or greater (Fig. 16C).  
For this reason, a concentration-range of 10 mg/L was selected for its cytotoxic effects in 
cancer cells while producing to cytotoxic effects in normal cells. 
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5FU(0.5mg/L)     -       +                    -        +                   -        +  
 
Figure 16. Effects of mango polyphenols and their metabolites on cell proliferation.  
A) Anti-proliferative activities of non-treated controls (Con), gallic acid (GA), 
methylgallate (MG), pyrogallol (PG) and low molecular fraction of mango polyphenols 
(ML) each at 1 mg/L for 48 h of exposure, B) Subsequent treatment of 10 mg/L ML or 
PG, followed by a 24 h exposure of 5-FU at 0.5 mg/L for 24 h, C) Anti-proliferative 
activities of ML and PG in non-cancer breast-fibroblast cells MCF12F. Values are the 
mean ± SEM (n=3). The different letters indicate significance at p < 0.05 (Tukey’s 
HSD). 
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Effects of Mango Polyphenols and Pyrogallol on Gene Expressions 
 Polyphenols are known to downregulate different vital constituents of the IGF1-
R/PI3K/AKT/mTOR-axis in cancer cell lines [127, 136, 137]. Based on the anti-
proliferative activities of ML and PG, the gene expression of constituents of the mTOR-
pathway were investigated in this study (Fig. 17A-D). After 24 h of exposure, mRNA of 
the extracellular protein IGF1-R was decreased by more than 40% when cells were 
treated with PG at 10 mg/L compared to 5-FU, which at the selected concentration did 
not significantly affect mRNA expression.  The combination of PG + 5-FU did also not 
significantly decrease mRNA expression of IGF1-R compared to control cells.  In 
contrast, ML mRNA expression of IGF1-R was increased compare to control cells, and 
conversely, in combination with 5-FU it decreased the gene expression of IGF1-R 
(Figure 17A).   Neither ML nor 5-FU altered the gene expression of AKT but the 
combination of both significantly reduced AKT mRNA.  ML may not have decreased the 
mRNA level of AKT, while PG alone and in combination with 5-FU decreased mRNA of 
AKT (Figure 17B).  mTOR mRNA levels were significantly decreased by ML and PG 
but in combination with 5-FU, these treatments did not potentiate the effects of 5-FU 
alone (Figure 17C).  ML and PG also decreased HIF1α mRNA but the co-treatment with 
5-FU did not potentiate the effects of 5-FU alone (Figure 17D).  While changes in 
mRNA expression allow limited conclusions about protein-activity along this pathway it 
indicates any potential reduction of protein production due to reduced mRNA expression 
[138, 139]. 
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Figure 17. Effects of mango polyphenols (ML) and pyrogallol (PG) on the gene 
expressions involved in the mTOR signaling.  
mRNA expressions following exposure to 10 mg/L ML or PG for 24 h with and without 
subsequent exposure to 5-FU at 0.5 mg/L for 24 h in MCF10DCIS.COM cells. (A) IGF-
1R, (B) AKT, (C) mTOR, and (D) HIF1. Values are the mean ± SEM (n=3). The 
different letters indicate significance at p < 0.05 (Tukey’s HSD). 
Effects of Mango Polyphenols and Pyrogallol on Protein Expression 
Total and phosphorylated protein levels provide a better characterization of the 
anti-proliferative activities of ML and PG as it represents an indication of the activity of 
a certain pathway. ML and PG significantly decreased total IGF-1R, and PG also 
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decreased phosphorylated protein levels. In addition, PG followed by 5-FU significantly 
reduced total protein levels compared to either treatment individually (Fig. 18A).  
Insulin receptor (IR) total protein was significantly reduced by both polyphenol 
treatments where ML also significantly reduced phosphorylated levels. PG in 
conjunction with 5-FU decreased total protein levels greater than either compound 
individually; however, this effect was not observed at the phosphorylated level (Fig. 
18B).  
 IRS1 was only significantly decreased at the total protein level with PG. A 
combination treatment with 5-FU and PG decreased total protein levels greater than each 
treatment individually. IRS1 phosphorylation levels were not significantly altered by 
either ML or PG (Fig. 18C). The polyphenol treated groups decreased both total and 
phosphorylated AKT protein levels. PG reduced total AKT protein levels to a greater 
extent than 5-FU alone (Fig. 18D). mTOR showed significantly decreased protein levels 
with both polyphenol treatments, and PG alone reduced mTOR total protein greater than 
50% compared to the control. Neither treatment altered mTOR phosphorylation. 5-FU 
alone elevated mTOR protein levels, and when pretreated with ML or PG, mTOR total 
protein was decreased (Fig. 18E). The downstream kinase P70S6K that is directly 
involved in cell proliferation upon mTOR activation was downregulated at both the total 
and phosphorylated protein levels by both ML and PG. Furthermore, when pyrogallol 
and 5-FU were combined, an additive effect was apparent for total protein expression 
(Fig. 18F). 
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Figure 18. Effects of mango polyphenols (ML) and pyrogallol (PG) on the protein 
expressions involved in the mTOR signaling.  
Expression of total and phosphorylated protein levels following 10 mg/L ML and PG 
treatment for 24 h followed by 24 h incubation with and without 5-FU at 0.5 mg/L. (A) 
IGF-1R, (B) IR, (C) IRS1, (D) AKT, (E) mTOR, and (F) P70S6K. Values are the mean ± 
SEM (n=4). The different letters indicate significance at p < 0.05 (Tukey’s HSD). 
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Discussion 
 Previous studies have demonstrated the anti-proliferative activities of 
polyphenols in cancer cells, while no cytotoxicity was observed in non-cancer cells 
within the same treatment concentration-range [60, 140, 141]. The concentrations 
selected for this study are within a physiological range, which can be expected to occur 
in vivo upon consumption of mango fruit or a dietary supplement [65, 142].  Conversely, 
few reports include the investigation of PG, a microbial metabolite, that occurs 
systemically after the ingestion of gallotannins [68, 143] as they occur in mangos and 
many other fruits and vegetables, teas and spices [144-147]. The results of this study 
confirm that mango polyphenols decrease proliferation in breast cancer cells that seem to 
be at least in part modulated by the mTOR-signaling axis [148].   
 ML and PG decreased proliferation in MCF10DCIS.COM, but did not decrease 
viability in the non-cancerous breast cell line MCF-12F at 10 mg/L. This initial result 
supplied justification for the dose concentration used through the duration of the study, 
because 10 mg/L had a cytotoxic effect in the breast cancer cell lines while displaying no 
cytotoxic effects in normal cells. The low molecular weight fraction is composed of 
multiple compounds, which included mono-galloyl glucoside, gallic acid, and 
hydroxybenzoic acid hexoside. In addition, our lab reported that mango polyphenols 
include galloyl diglucoside, coumaric glycoside, dihydrophaseic acid glucoside, ferulic 
acid hexoside, eriodictyol-O-hexoside.[130] A complete extract, along with the single 
compound PG was selected due to their similarities in effect observed in the proliferation 
assay, and allowed for a comparison between an extract containing multiple polyphenols 
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to a single polyphenolic metabolite with physiological relevance  that has yet to be 
investigated in a breast cancer model. Intuitively, each of these compounds can be 
expected to differ in anti-proliferative activities. Previous studies that investigated the 
independent and combinational anti-proliferative efficacy of pomegranate polyphenols, 
and they demonstrated that an extract containing punicalagin, ellagic acid, and 
pomegranate tannins, had a greater anti-proliferative effect on colon cancer cell lines 
(HT-29 and HCT119), compared to treatment with any of the individual 
polyphenols[149].  This demonstrates how an extract containing a spectrum of 
polyphenols could produce a synergistic or additive effect compared to single 
polyphenol compounds. The same conclusion was drawn in a study that evaluated a total 
cranberry extract versus its phytochemical constituents in oral, colon, and prostate 
cancer cell lines.[150] 
Pyrogallol is formed in the gastrointestinal tract through tannase enzymes. The 
intestinal conversion rate of tannins to pyrogallol has not yet been established. However, 
in a previous clinical study performed in our laboratory, we quantified 87.9 mg of gallic 
acid metabolites with the majority being pyrogallol glucuronide, pyrogallol sulfate, and 
methyl-pyrogalloyl sulfate as urinary metabolites after 400 g mango fruit intake (130.13 
mg GAE of gallotannins). [151] With this, the concentration-range of pyrogallol used in 
this study includes physiological levels after the intake of food and reaches into a 
concentration range that may be expected after prolonged consumption or higher intake 
levels of tannins, e.g. from a dietary supplement.  
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5-FU is a widely used genotoxic cancer drug that is frequently used in breast 
cancer treatment, however, this drug has severe side effects that include cardiotoxicity, 
mood disorders, and neurological damage.[109, 148] The concentration of 5-FU selected 
for this study (3.85 M) was far below the IC50 in cancer cells to determine whether a 
co-treatment with polyphenols might potentiate the anti-proliferative activities of 5-
FU,[152] thus indicating a potential for decreasing the required dose in cancer treatment 
which would reduce the severity of observed side effects.[110] A low concentration of 5-
FU was selected to detect any possible synergistic activities with ML or PG. A higher 
concentration of 5-FU would have potentially masked these effects. Previously, a 
combination of 5-FU and genistein resulted in decreased cyclooxygenase-2 levels 
(COX-2) compared to groups only treated with 5-FU, which had significantly elevated 
COX-2 levels in HT-29 colon cancer cells. This effect was attributed to the reactive 
oxygen species produced by the genistein which activated AMPK and decreased COX-2 
expression. In contrast to this previous publication, the concentration-range selected for 
this study was much lower and this may have caused the lack of additive, potentiating or 
synergistic activities. Overall, in this study, the selected low concentrations of 5-FU and 
the low concentrations of polyphenols did not produce overwhelming evidence of an 
additive, potentiating or synergistic interaction between ML, PG, and 5-FU as it was 
observed in previous publications. 
The IGF-1R- AKT/mTOR signaling axis is a major pathway involved in the 
regulation of proliferation.[96, 153-155] Previously, treatments of cancer cells with 
polyphenols have elicited a reduction of activities in this pathway; however, the effects 
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of a physiological microbial metabolite of polyphenols have rarely been investigated. In 
this study, ML decreased mRNA levels for both mTOR, and downstream transcription 
factor HIF1α. At the protein level, ML downregulated the cell surface receptor IGF-IR 
and P70S6K, a kinase regulated by mTOR, and may exert an extracellular and 
intracellular effect influencing both components. Previously, treatment with polyphenols 
showed extracellular effects through the blockage of membrane receptors such as 
epidermal growth factor receptor in combination with an intracellular effect through the 
quenching of free radicals.[156, 157] It could be rationalized that mango polyphenols 
exerted an effect both intracellularly and extracellularly, where the larger molecular 
weight compounds exert more effect on the cell surface, and the smaller compounds are 
able to cross the phospholipid membrane and bind with cytosolic or nuclear 
proteins.[158-160] 
As initially hypothesized, both polyphenol-treatments demonstrated differential 
activities within the AKT/mTOR signaling axis in vitro and a summary of the results can 
be seen in Table (7).  Compared to the low concentration-range of 5-FU, ML exerted a 
greater reduction on mRNA and protein along the mTOR pathway. ML significantly 
reduced IGF1-R, IRS1, IR, mTOR, and P70S6 protein levels compared to 5-FU. There 
was no consistent interaction observed between ML and 5-FU that would justify further 
investigation in this co-treatment paradigm within the selected concentration-range.  ML 
decreased mRNA levels of mTOR and HIF1α, as well as total protein for IGF-1R, IR, 
AKT, mTOR, and P70S6K, and phosphorylated protein levels of IR, AKT, and P70S6K 
compared to the control. ML may not have decreased the mRNA level of AKT, 
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Table 7. Overview of proposed anti-proliferative mechanism of polyphenols 
involving IGF-1R-AKT/mTOR signaling axis. 
 
however, it is common for mRNA and protein expressions not to be fully correlated 
[161, 162]. In this study, AKT protein expression was decreased while the mRNA 
concentrations were not affected at the selected time point of 24 h. In addition, it is 
possible that with the selected exposure window (24 h) data did not capture an effect of 
PG on AKT mRNA, which might be changed at earlier time points.[163] PG, a central 
intestinal microbial metabolite of gallotannins, was selected for this study as it 
systemically occurs after the consumption of gallotannins.[68] In initial screening, the 
anti-proliferative effect of PG exceeded those of gallic acid and other mango-derived 
polyphenols. PG decreased mRNA levels of IGF-1R, AKT, mTOR, and HIF1α, as well 
as total protein for IGF-1R, IR, IRS1, AKT, mTOR, and P70S6K, and phosphorylated 
protein levels of IGF-1R, AKT, and P70S6K compared to the control. When co-treated 
with 5-FU, an additional reduction of protein-expression and protein phosphorylation 
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was observed along the mTOR axis compared to the individual 5-FU treatment. It 
indicates that PG may have a potential to enhance the anti-proliferative activities of 5-
FU, thus decreasing the required dose of 5-FU. Further research would be necessary to 
determine whether the enhanced anti-proliferative action from the co-treatment of 
mango polyphenols, PG with 5-FU in vitro can be reproduced in animal models. 
Overall, this study demonstrates that mango polyphenols have an anti-
proliferative effect on DCIS breast cancer in vitro at physiologically relevant 
concentrations, and this mechanism could be partially attributed to the ability of these 
polyphenols to down-regulate multiple key constituents along the AKT/mTOR signaling 
axis. 
56 
CHAPTER III 
POLYPHENOLICS FROM MANGO (MANGIFERA INDICA L.) SUPPRESS BREAST 
CANCER DUCTAL CARCINOMA IN SITU PROLIFERATION IN VIVO THROUGH 
THE ACTIVATION OF AMPK PATHWAY AND SUPPRESSION OF MTOR 
Summary 
The objective of this study was to assess the underlying mechanisms of mango 
polyphenols resulting in decreased proliferation and tumor volume in ductal carcinoma 
in situ (DCIS) breast cancer. Utilizing a MCF10DCIS.com xenograft model, the 
hypothesis that mango polyphenols reduce signaling along the AKT/mTOR axis while 
upregulating AMPK was tested. Tumor volumes were significantly reduced more than 
50% in both the mango (MG) and pyrogallol (PG) treated athymic mice at 0.8 mg 
GAE/day and 0.2 mg/day, respectively, following 4 weeks of oral administration (n=10 
per group). Both treatments decreased mRNA expression involved in the mTOR 
pathway by up to 80%. Total protein levels were significantly decreased by greater than 
25% for IRS1, 45% for AKT, and 40% for mTOR in both treatment groups compared to 
the control. Phosphorylated protein levels of IR, IRS1, IGF-1R, P70S6K, and ERK were 
significantly reduced by PG, and MG significantly reduced IR, IRS1, IGF-1R, and 
mTOR. The level of Sestrin2, an activator of AMPK, was significantly elevated in MG 
and PG treated tumors, while MG significantly elevated AMPK phosphorylation and PG 
elevated LKB1. The modulation of reactive oxygen species (ROS) generation and the 
AMPK pathway by both compounds were confirmed in vitro. These results suggest that 
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mango polyphenols and their major microbial metabolite pyrogallol may inhibit 
proliferation of DCIS breast cancer through upregulating of AMPK and downregulating 
of the AKT/mTOR pathway. 
 Introduction  
 Breast cancer was estimated to contribute almost 30% to newly diagnosed 
cancers with 232,670 cases diagnosed in 2014 [164], contributing to an estimated 40,000 
deaths [165]. Ductal carcinoma in situ (DCIS) stage occurs directly before metastasis. 
Delaying the onset of metastasis may have significant implication in extending survival, 
specifically since most deaths occur because of complications arising from multiple 
organ system involvements rather than to primary cancer site tumors [166]. Treatment of 
DCIS breast cancer, most commonly with a mastectomy, has a ten year survival rate of 
98-99% [32]. Given the high incidence and mortality associated with breast cancer, an 
ongoing effort in drug development along with the refinement of current treatment 
options is necessary to provide the best therapeutic strategies. Currently, available 
treatment options commonly cause adverse side effects contributing to both a decreased 
quality of life and decreased compliance amongst patients [167, 168]. Dietary 
polyphenols are advantageous, based on their demonstrated efficacy and lack of 
deleterious side effects and therefore could be a potential candidate as treatment 
alternatives to conventional synthetic small molecules [169-171]. 
 Mango (Mangifera indica L.), once considered an exotic fruit, is now readily 
consumed in the U.S [56]. Mango is rich in polyphenolic moieties including gallic acid, 
gallotannins, galloyl glycosides and flavonoids, which all have been shown to have 
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potential health benefits associated with their consumption [59, 172, 173]. Polyphenolic 
profile and concentrations are dependent on variety, location, harvest conditions, and 
processing methods [174]. Mango polyphenolics have been demonstrated to have anti-
inflammatory and cancer-cytotoxic properties in multiple cancer types including 
malignancies of the colon and breast [175, 176]. Gallic acid is a unique 
trihydroxibenzoic acid that is found in high concentrations in mango [177]. Gallotannins 
consist of gallic acid and other molecules, and may be broken down by lactobacilli to 
release free gallic acid or its decarboxylated form pyrogallol within the gastrointestinal 
tract (GI). Pyrogallol is a unique metabolite that is formed by decarboxylation of gallic 
acid by intestinal microflora, and has been shown to have health promoting properties in 
different disease models [68, 76]. 
The AKT/mTOR pathway is dysregulated in breast cancer, and has been a target 
for breast cancer therapy [178]. Previously, we reported that the anti-inflammatory and 
anti-cancer effects of mango polyphenols results through modulation of the mTOR 
pathway [179, 180]. 5’ AMP-activated protein kinase (AMPK) is responsible for 
maintaining energy homeostasis within the cells and is activated through the 
accumulation of Sestrin protein, and ultimately the activation of this pathway culminates 
in the inhibition of mTOR along with the activation of autophagy [181, 182]. The 
expression of AMPK is known to be activated by reactive oxygen species (ROS), 
therefore, the ROS-activated AMPK pathway could be modulated by pro-oxidants [183-
185]. 
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The objective of this research is to establish if the mango polyphenols and 
pyrogallol inhibit proliferation of breast cancer cells in a xenograft tumor model. Our 
hypothesis was that mango polyphenols and their major intestinal metabolite pyrogallol 
may have anti-cancer effects on ductal carcinoma in situ through signaling along the 
AKT/mTOR axis while upregulating AMPK. This is the first study to investigate the 
inhibition of ductal carcinoma in situ breast cancer by mango polyphenols and their 
major intestinal metabolite pyrogallol in vivo. 
Materials and Methods 
Extractions and Chemical Anaylsis 
 The polyphenolic extract from mango cv. Keitt was prepared as previously 
described with some modifications [130]. Briefly, 2 kg of pulp was homogenized and 
extracted with 2 L of 1:1 Methanol: Acetone for 30 min proceeded by separation of 
insoluble solids with cheese cloth. Remaining solids underwent two additional 
extractions with 1 L of solvent mixture, and was evaporated with a Buchi RII Rotavap 
(Waltham, MA) at 45°C under vacuum. Polyphenols were concentrated using a 10 g 
Waters C18 sample preparatory column that was prepared with 10 columns volumes of 
0.1 M HCl MeOH and 0.01 M HCl H2O. Polyphenolics were eluted with 200 mL of 0.1 
M HCl MeOH. To retain water-soluble phenolics that did not bind to C18, the unbound 
fraction was extracted twice by 1:1 ratio of sample: ethyl acetate. The C18 eluent and 
ethyl acetate fractions were collected together, evaporated under vacuum to dryness, and 
brought up to 50 mL in 1% Citric Acid. This process was repeated 9 additional times and 
extracts were pooled together to make a volume of 500 mL for the final extract. Total 
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soluble phenolics was calculated for the final extract spectrophotometrically using the 
Folin-Ciocalteu assay with values expressed as mg gallic acid equivalents (GAE)/L.  
Additional a detailed characterization and quantification of individual polyphenolics was 
performed by use of a HPLC-MS Thermo Finnigan Surveyor HPLC-PDA coupled to a 
Thermo Finnigan LCQ Deca XP Max MSn ion trap mass spectrometer equipped with an 
ESI ion source (Thermo Fisher, San Jose, CA) Injections were made into the column by 
use of a 25 μL sample loop followed gradient separations were performed using a 
Phenomenex Kinetex C18 column (150 × 4.6 mm, 2.6 μm) at room temperature. Mobile 
phase A was 0.1% formic acid in water, and mobile phase B was 0.1% formic acid in 
methanol run at 0.4 5mL/min. The gradient was run with 0% phase B for 2 min and 
changed to 10% phase B at 4min and held to 10min, from 10 to 40% phase B in 25min, 
from 40 to 65% phase B in 35min, and from 65 to 85% phase B in 41 min and held to 50 
min before returning to initial conditions. The electrospray interface worked in negative 
ionization mode. Source and capillary temperatures were set at 275°C, source voltage 
was 4.00 kV, capillary voltage was set at −42 V, and collision energy for MS/MS 
analysis was set at 35 eV. The instrument operated with sheath and auxiliary gas (N2) 
flow rates set at 20 and 10units/min, respectively.  Pyrogallol was order from Sigma-
Aldrich (St. Louis, MO) and was brought up in 0.2 M solution of citric acid buffer at a 
pH of 3.5. 
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Cell Culture 
Human breast cancer cell line MCF10DCIS.COM were obtained from Astelrand, 
Inc. (Detroit, MI) and cultured in DMEM-F12 media (Invitrogen, Carlsbad, CA) 
supplemented with 10% horse serum (Atlanta Biologicals, Lawrenceville, GA). 
Xenograph Study 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at Texas A&M University before their initiation. Female athymic BALB/c 
nude mice at approximately three weeks of age were ordered from Harlan Teklad 
(Houston, TX). MCF10DCIS.com cells (5 X 104 cells) were harvested and mixed with
50 µL of Matrigel (BD Bioscience, San Jose, CA) and stored on ice until implantation. 
Mice were implanted subcutaneously into the mammary pad (bilaterally). Tumors were 
allowed to proliferate one week before the initiation of dosing. Animals were orally 
gavaged 100 µl twice daily with either MG or PG to achieve a daily exposure of 0.8 mg 
GAE/day or 0.2 mg/day, respectively (n=10 per group). Control animals received the 
same dosing regimen with a vehicle of the 0.2 M citric acid buffer (pH 3.5). Tumors size 
were measured weekly with calipers. Body weights were recorded weekly and at the 
time of necropsy. Mice were killed 4 weeks after the initiation of dosing, and tumors and 
organs of interest were either preserved via fixation in 10% neutral buffered formalin or 
flash-frozen in liquid nitrogen [186].  
Analysis of mRNA Expression by Real-time PCR 
Total RNA was isolated from tumor samples using a mirVana miRNA Isolation 
kit (Applied Biosystems, Foster City, CA). cDNA was synthesized from the isolated 
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RNA using of a Reverse Transcription Kit (Invitrogen Corp., Grand Island, NY). Primers 
were designed using the Primer Express Software Version 3. (Applied Biosystems, 
Foster City, CA) and purchased from Integrated DNA Technologies Inc. (Coralville, IA). 
qRT-PCR was conducted on an ABI Prism 7900 Sequence Detection System (Applied 
Biosystems, Foster City, CA) using SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA) [186]. 
Multiplex Bead Assay 
 Xenographic tumor samples collected at the time of necropsy were homogenized 
in tissue protein extraction reagent (Invitrogen Corp., Grand Island, NY). Protein (50 µg) 
samples was utilized to determine the levels of pro-inflammatory cytokines including 
CRP, TNF-, and IL-1, and the total and phosphorylated protein levels of key 
components of the mTOR pathway utilizing multiplex kits and protocols (Millipore, 
Billerica, MA). The analysis was performed using a Luminex L200 (Luminex, Austin, 
TX). Data was analyzed using Luminex xPONENT Version 3.1 [175]. 
Western Blot 
Protein samples were diluted appropriately to achieve 60 ug total protein, which 
was loaded and run on a 4-12% sodium dodecyl-polyacrylamide gel. The gel was 
transferred for 1 h at 350 mA onto a PVDF membrane. The membrane was probed with 
the primary antibodies against Sestrin 2, Becklin, ULK, p-ULK, AMPK, p-AMPK, 
mTOR, p-mTOR, and LKB1 (Cell Signaling Technology, Danvers, MA). Βeta-actin was 
used as the endogenous control (Sigma, St Louis, MO). 
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ROS Generation 
 MCF10DCIS.com cells were seeded at a density of 5,000 cells/well in a 96-well 
plate and allowed to attach overnight. Following attachment, Cells were treated with 
either MG or PG treatment for 24 h at a concentration range from 1-20 mg GAE/L 
followed by treatment with 5 mM dichloro-dihydro-fluorescein diacetate (DCFH-DA) 
for 30 min at 37°C. Following the 30 min incubation, the medium was removed, and 100 
µl Dulbecco's Modified Eagle Medium (Invitrogen, Carlsbad, CA) containing no phenol 
red was added. The fluorescent signal was measured at 480 nm excitation and 520 nm 
emission with a FLUOstar Omega plate reader (BMG Labtech Inc., Durham, NC) [187]. 
Cell Proliferation and Cell Cycle Kinetics 
MCF10DCIS.com cells were seeded at a density of 15,000 cells/well in a 24-well 
plate and allowed to attach overnight. The glutathione pretreatment groups received 5 
mM glutathione for 3 h and then either MG or PG treatment for 24 h at 10 mg/L. After 
24 h cells were detached using trypsin. Proliferation and viability were assessed using a 
Muse Cell Analyzer (Millipore, Billerica, MA). For the cell cycle kinetics, 
MCF10DCIS.com cells were treated with either MG or PG at 10 or 20mg GAE/L for 24 
h and then harvested for analysis. The MUSE ® Cell Cycle Kit and protocol were used 
(EMD Millipore, Darmstadt, Germany). Briefly, cells were fixed in 70% ethyl alcohol at 
-20°C overnight. Cells were then resuspended in 200 µL of Muse Cell Cycle Reagent 
and incubated at room temperature for 30 min protected from light. Samples were then 
run in the Muse Cell Analyzer (EMD Millipore, Darmstadt, Germany).  
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Mitochondrial Membrane Potential 
 MCF10DCIS.com cells were seeded overnight and then treated with either 10 or 
20 mg GAE/L MG or PG for 24 h. Cells were suspended in assay buffer and then added 
to MitoPotenital working solution, which consisted of Muse MitoPotential Dye and 
assay buffer (EMD Millipore, Darmstadt, Germany). Cells were incubated for 20 min at 
37°C in a CO2 incubator. Following incubation 5 µL Muse MitoPotential 7-ADD reagent 
was added to each sample and allowed to sit at room temperature for 5 min. Samples 
were run in the Muse Cytometer (EMD Millipore, Darmstadt, Germany). 
Molecular Modeling and Docking 
 The 3D coordinates of human α2β1γ1 AMPK complex was retrieved by the 
Protein data bank (Structure ID= 4CFF) [188]. The model was energetically refined in 
the internal coordinate space with Molsoft ICM software (MolSoft LLC, San Diego, 
CA) as previously described [189]. In addition, molecular docking was run as previously 
reported [175, 189]. 
Small Interfering RNA (siRNA) Transfection of MCF10DCIS.COM Cells 
 MCF10DCIS.com cells were transfected for 6 h with siRNA targeting 
AMPK or with a control siRNA with Lipofectamine RNAi MAX (Invitrogen Corp., 
Grand Island, NY). Following transfection media was replaced with treatment media 
containing either 10 or 20 mg/L of PG or 10 mg GAE/L of MG for 24 h. After treatment 
mRNA and protein were isolated following the same procedures previously mentioned.  
Statistical Analysis 
 The sample size was determined using a priori statistical power analyses (p =  
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0.05, power = 0.85) [186]. Quantitative data represent the means ± SE. Data was 
analyzed by one-way analysis of variance using JMP 10 (SAS Institute Inc., Cary, NC). 
Dunnett post hoc multiple comparisons or Tukey’s HSD were used (p < 0.05) to 
determine statistical difference between treatment groups. 
Results 
Polyphenol Composition of Mango Extract by HPLC-MS 
The polyphenol profile and concentration of the mango extract was determined 
using HPLC-MS analysis (Figure 19) and were as following: gallic acid at 16.89 mg/L, 
ester-monogalloyl glucoside (2 different isomers) at 174.75 mg/L and 22.74 mg/L, and 
p-hydroxybenzoic acid glycoside at 81.94 mg/L. Additionally, unresolved gallotannins 
were identified. 
Figure 19. Representative HPLC chromatograph of mango polyphenols (280 nm).  
Tentative peak assignments showing the presence of: 1 Ester monogalloyl glucoside 
(149 mg/g of total phenolics), 2 Gallic acid (14 mg/g), 3 Ester-monogallol glucoside (19 
mg/g), 4 p-Hydroxybenzoic acid glycoside (69 mg/g), and gallotannins. 
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Effects of Mango Polyphenols (MG) and Pyrogallol (PG) in Athymic Nude Mice 
Xenographed with MCF10DCIS.COM Cells 
Based on the previous studies of the effects of MG and PG that resulted in 
decreased proliferation of MCF10DCIS.com in vitro primarily through the modulation 
of the AKT/mTOR signaling axis, we followed up with an assessment of these 
treatments in an in vivo xenograft model. Animals that were orally treated with 0.8 mg 
GAE/day MG or 0.2 mg/day PG had significantly reduced tumor volumes compared to 
the control group at weeks 3 and 4.  As can be seen in Figure 20A, at week 3, tumor 
volumes of PG and MG treated animals were reduced approximately 75% and 45%, 
respectively, compared to the control animals. At 4 weeks, MG and PG had a similar 
effect on tumor volumes, which was greater than a 70% reduction compared to the 
control. These results indicate significant retardation in tumor growth by both treatments 
following 4 weeks of oral exposure. 
Tumors collected at the time of necropsy were processed and assayed for 
cytokine levels based on previous reports suggesting mango polyphenols reduce 
inflammation in various disease models, and these results are present in Figure 20B 
[130]. Previous reports provided ample justification for screening a few key 
inflammatory markers to determine if these treatments were able to alter expression in 
this in vivo model for breast cancer. MG significantly decreased CRP and TNF-α levels 
by 20% and 35% respectively compared to the control. Tumors from PG treated animals 
had significantly reduced IF-1β, approximately 40%, compared to the control.  
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Genes along the mTOR signaling pathway were quantified to determine if these 
compounds had an effect at the mRNA level, which could impact total and 
phosphorylated protein levels.  MG and PG decreased the mRNA expression of multiple 
genes along the AKT/mTOR signaling axis in xenographed tumors (Figure 21). 
Upstream of mTOR, IGF1R and IRS1 mRNA levels were significantly reduced by both 
treatments with IGF-1R and IRS1 being reduced greater than 60% compared to control 
tumors.  mRNA levels were also reduced downstream of IGF-1R and IRS1 
Figure 20.  Effects of mango polyphenols (MG) and pyrogallol (PG) in athymic 
nude mice xenografted with MCF10DCIS.COM cells.  
(A) Tumor volumes over four weeks were decreased by MG or PG in athymic mice 
compared to vehicle treated controls (n=10 per group). *p < 0.05 compared to the 
control (Dunnett’s test). (B) Pro-inflammatory cytokine levels in tumor following four 
week exposure to 0.8 mg GAE/day MG or 0.2 mg/day PG. 
and included decreased mRNA levels for PI3K and AKT.  Both of these were reduced to 
a similar percentage with MG treatment reducing either level by nearly 80% while PG 
treatment reduced PI3K and AKT by 60%.  The mRNA levels of mTOR were reduced 
A 
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Figure 21. Effects of mango polyphenols (MG) and pyrogallol (PG) on mRNA levels 
in tumors following four week exposure to 0.8 mg GAE/day MG or 0.2 mg/day PG 
in athymic nude mice xenografted with MCF10DCIS.COM cells.   
60% and 50% for MG and PG treatment, respectively.  ERK mRNA levels were also 
reduced similarly with a 60% reduction with MG treatment and 50% reduction in PG 
treated animal tumors.  Overall all mRNA investigated were reduced at least 50% with 
either treatment along the AKT/mTOR signaling axis.  Because the mTOR signaling axis 
is so interconnected with numerous cellular functions, including proliferation, it is 
hypothesized that this genetic downregulation is a least in part responsible for the 
reduced tumor sizes in the treatment groups. 
Following the mRNA analysis, tumor samples were run both with a multiplex 
bead assay and western blot to determine treatment effects on total and phosphorylated 
protein levels. The Luminex bead assay results focused on the effects of mTOR 
signaling and were conducted to allow a more direct comparison to the results we 
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previously published in vitro (Figures 22A and 22B). The MG and PG treatments altered 
both total and phosphorylated protein levels along the AKT & mTOR signaling axis. 
Total protein levels for IRS1 were reduced 25% for MG and 40% for PG while AKT and 
mTOR were significantly decreased approximately 40% by both treatments compared to 
the control. MG treatment was significantly reduced phosphorylated protein levels for 
the following: IR, IRS1, IGF-1R, and mTOR by 30%, 50%, 35%, and 45% respectively. 
PG treatment had a similar effect; however, it did not significantly reduce p-mTOR 
levels but did significantly decrease the downstream indicator of mTOR, p-P70-S6k by 
80%. This downregulation could also be attributed to the downregulation seen in p-ERK 
levels, which were reduced more than 40%. 
Western blots were conducted to examine further a potential mechanism of action 
that extended beyond the effects of mTOR signaling. AMPK was a novel pathway to 
investigate based on previous publications suggesting polyphenols as ROS-generating 
compounds [183-185]. Animal tumors that received the MG or PG treatment regimen 
had increased Sestrin2 and Becklin protein levels compared to the control. Sestrin2 is 
activated when elevated levels of ROS are present, and similarly, oxidative stress is also 
able to activate Becklin, which can ultimately trigger apoptosis or autophagy [181, 182]. 
Both treatments had no significant effects on total AMPK levels; however, p-AMPK was 
up-regulated in both treatment groups (Figures 23A and 23B). AMPK is a key regulator 
in maintaining cellular homeostasis, and its upregulation coincides with the down 
regulation of p-mTOR [190].  The reduction in p-mTOR in the MG treated animal 
tumors could also be potentially related to the elevated total ULK and p-ULK levels. 
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Figure 22. (A) total protein levels, and (B) phosphorylated protein levels in tumor 
following four week exposure to 0.8 mg GAE/day MG or 0.2 mg/day PG in athymic 
nude mice xenografted with MCF10DCIS.COM cells. 
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While the western blot data demonstrated a trend in upregulated AMPK and 
downregulated mTOR, further examination, possibly at higher doses, would be required 
to explore whether a causal relationship can be ascertained. 
Effects of Mango Polyphenols (MG) and Pyrogallol (PG) in MCF10DCIS.COM Cells 
Due to the results obtained in vivo, further investigation in vitro was warranted to 
elucidate a more definitive mechanism of action leading to the upregulation of AMPK 
signaling from the MG and PG treatments.  A 5-20 mg/L dose range was selected based 
on previous work in a non-cancerous breast cell line that determined this concentration 
range had no effect on viability. In our previous works, both MG and PG decreased 
MCF10DCIS.com proliferation by 26 and 31% respectively compared to the control. At 
the highest level, proliferation was reduced as much as 61% for PG treated cells and 
48% with MG treatment. Following this, both treatments were examined for ROS 
production because elevated ROS levels have shown to activate AMPK. MG and PG 
increased the generation of cytosolic ROS, however PG produced ROS to a greater 
degree and in a dose-dependent manner compared to MG.  PG produced significantly 
more ROS, approximately 2.5 fold, at concentrations as low as 1 mg/L compared to 
control. At 10 mg/L MG and PG had ROS levels, 2.75 and 3.75 fold greater than 
controls, respectively. Doubling the treatment concentration to 20 mg/L MG did not 
increase ROS generation, but PG ROS generation continued to increase to 4.75 fold 
greater than controls (Figure 24A). 
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Figure 23. (A) Western blot total protein and phosphorylated protein levels in 
tumor following four week exposure to 0.8 mg GAE/day MG or (B) 0.2 mg/day PG 
in athymic nude mice xenografted with MCF10DCIS.COM cells.  
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Figure 24. Effects of mango polyphenols (MG) and pyrogallol (PG) in 
MCF10DCIS.COM cells. 
(A) MG and PG induced ROS generation following 24 h treatment in 
MCF10DCIS.COM cells. (B) GSH pretreatment (5mM) attenuated the anti-proliferative 
effects of both MG and PG at 10 mg/L for 24 h. 
Based on these findings, it was hypothesized that ROS may be a contributing 
factor involved in the anti-proliferative mechanisms of MG and PG. To test this 
hypothesis, cells were pre-treated with 5 mM GSH to determine whether inclusion of an 
antioxidant would negate the anti-proliferative effects of either the MG or PG 
MG    PG 
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treatments. Figure 24B shows either treatment at 10 mg/L significantly reduced 
MCF10DCIS.com proliferation compared to the control after 24 h. Cells that were co-
treated with GSH for 4 h did not have a significant difference in cellular proliferation 
compared to the control. This data continued to support the hypothesis that the ROS 
producing nature of these compounds is contributing to their anti-proliferative capacities. 
More experimentation was performed to determine the effects of these treatments 
on both cell cycle kinetics and mitochondrial function (Figures 25A & 25B). Both 
treatments significantly affected cell cycle kinetics where the lower concentrations 
mainly affected the G0/G1 phase, while the higher levels increase the amount of cells 
halted in the S phase.  MG and PG at a concentration of 10 mg/L significantly decreased 
cells in the GO/G phase, 10% and 11% respectively, and did not alter the percentage of 
cells in the S phase compared to control cells. Both treatments significantly increased 
cells halted in the G2/M phase compared to the control, 3% in MG treated and 8% in PG 
treated. At the higher concentration of 20 mg/L, MG significantly decreased cells in the 
G0/G phase similarly to the lower concentration. MG and PG treatments significantly 
decreased cells in the G2/M phase by 9% and 8% respectively.  The greatest effect seen 
from this higher treatment group was in the S phase with MG treatment increasing cells 
halted in this phase by 27% and PG treatment increased by 18%. The increase of cells in 
the S phase with MG treatment increasing cells halted in this phase by 27% and PG 
treatment increased by 18%. The increase of cells in the S phase could be a result of 
ROS-induced DNA damage. The only effect from the mitochondrial potential assay was 
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Figure 25. (A) MG and PG have varied effects on cell cycle progression 
determinant on concentration. (B) PG induced the mitochondrial membrane 
potential at 20 mg/L. All of the experiments were performed at least three times, and 
the results were expressed as the mean ± SEM (n=3). *p < 0.05 compared to the control 
(Dunnett's test). 
 
 
 
a significant increase in dead depolarized cells at 20 mg/L PG after 24 h, increasing the 
number of depolarized cells to nearly 13% more than was found in control cells. 
 
A 
B 
76 
Effects of Pyrogallol (PG) on the AMPK in MCF10DCIS.COM Cells 
Because of the elevated ROS production demonstrated by PG in vitro, molecular 
docking was performed against the allosteric modulatory site of the activated human 
α2β1γ1 AMPK in complex with A769662 (Protein Data Bank, Structure ID= 4CFF) 
[188]. Initially, protocols were validated by docking A769662 into the binding site of 
interest. The compound docked with the score of -32.61 reproducing the non-covalent 
binding pattern observed experimentally [191]. PG docked into the same pocket (β1 
subunit) with the score of -14.43. The natural compound established hydrogen bond 
interactions with the side chain of Lys 31, the backbone carbonyl of Gly 19 and most 
importantly, with the phosphate group of pSer 108 (Figure 26A). Residues pSer 108 
(carbohydrate binding module β1 subunit) and Lys 31 (β1 subunit) are part of a non-
covalent network conserved in mammals [191]. This network is critical for the stability 
of the activated form of AMPK which subsequently protect residue Thr 172 (catalytic 
module α2 subunit) from dephosphorilation [192]. In addition, mutation of Ser 108 into 
an alanine significantly decreased binding and activation of A769662 and 991 [192]. The 
low molecular weight of this compound along with the ability for it to cross 
phospholipid membrane made it plausible that the chemical structure of PG may also be 
a factor in activating AMPK and supply structural integrity to the AMMPK complex. 
Further investigation was conducted examining if PG could increase AMPK 
levels following knockdown with siRNA (Figures 26B &C). MCF10DCIS.com cells 
transfected with siRNA had reduced mRNA, total and phosphorylated protein levels, 
compared to the control. In the case of mRNA, PG treatment was able to significantly 
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increase AMPK mRNA levels by nearly 40%, while MG treatment had no effect on 
mRNA levels. Western blot analysis revealed that this pattern continued to the total and 
phosphorylated protein levels. Conclusively, PG treatment upregulated AMPK levels 
following its knockdown in MCF10DCIS.com cells. 
Discussion 
In this study, we demonstrated the anti-cancer effects of mango polyphenols and 
pyrogallol in a DCIS xenograft model. Mango polyphenols have been previously 
reported to have cytotoxic activities in cancer cells, however, DCIS- specific breast 
cancer has not been previously investigated [90]. Previously, we have reported the 
ability of mango polyphenols to downregulate the mTOR pathway in vivo by targeting 
upsteam regulators such as PI3K and AKT [186]. The mechanism proposed here, 
continues to elucidate the activities of these compounds on mTOR signaling both in vitro 
and in vivo with particular emphasis on the AMPK-mTOR-axis.  The chromatogram 
from the MG extract contained four major polyphenols and residual gallotannis. It was 
reported that gallotanins can be broken down firstly though tannase enzymes produced 
by GI bacteria such as Lactobacillus Plantarum, separating the gallic acid moieties along 
the meta-depside bonds [193, 194]. The digestion leads to elevated free gallic acid 
levels, and decarboxylase enzymes produce pyrogallol [195]. 
 In the athymic xenograft mouse experiment, tumor sizes were significantly 
reduced in those animals that received MG or PG treatment compared to the control. The 
reduction in volume was hypothesized to be a result of mTOR downregulation due to the 
fact that mTOR is a key regulator of cellular proliferation and has previously been 
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Figure 26. Effects of pyrogallol (PG) on the AMPK in MCF10DCIS.COM cells.  
(A) Docking of PG into the allosteric modulatory site of human α2β1γ1 AMPK holo 
complex (Protein Data Bank, Structure ID= 4CFF). The secondary structure is displayed 
as ribbon colored in yellow (β1 subunit) and orange (Carbohydrate-binding module β1 
subunit). Residues are displayed as sticks and colored by atom type with carbon atoms in 
green. The ligand is displayed as sticks and colored by atom type with carbon atoms in 
magenta. Hydrogen bond interactions are displayed as black dashed lines (Molsoft 
ICM). (B) mRNA expression levels of AMPK in MCF10DCIS.COM cells with and 
without siRNA followed by exposure to either PG or MG for 24 h. The results were 
expressed as the mean ± SEM (n=3). The different letters indicate significance at p<0.05 
(Tukey’s test). (C) Western blot results following siRNA knockdown of AMPK in 
MCF10DCIS.COM cells followed by exposure to PG for 24 h. 
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reported to be affected by polyphenol exposure [96, 154]. Animals were treated with 
concentrations that were approximately 1-2% and less than 1% of the LD50 levels for 
pyrogallol and gallic acid, respectively [77, 196], and are equivalent to a high dietary 
intake of mango or dietary supplement with pyrogallol in humans [151]. Animals 
showed no adverse effects as determined by daily observation, body weight gain, and 
liver weights at these doses. In this study, MG decreased CRP and TNF-α in tumor tissue 
while IL-1β levels were reduced in tumor tissue in animals exposed to PG. These 
findings support previous reports demonstrating that anti-inflammatory activities of 
gallic acid derivatives where at least some of the beneficial effects of gallic acid and 
related polyphenols consumption contributed to their ability to reduce inflammation 
[131, 158, 197].  
 In this study, genes investigated along the mTOR pathway were downregulated 
by treatment with MG or PG by at least 40%. The downregulation at mRNA-level of 
these critical components carried over to total and phosphorylated protein levels. 
Multiplex-bead analysis demonstrated a downregulation of both total and 
phosphorylated mTOR protein levels by MG and a downregulation of total mTOR and 
the downstream indicator of activity p70S6K by PG. Both treatments caused increased 
p-AMPK levels which could be partially attributed to elevated Sestrin2 or Beclin protein 
levels [175, 190, 198]. Sestrin2 can activate AMPK downstream of tumor suppressor 
P53 leading to the inhibition of mTOR [199]. Beclin activation leads to the recruitment 
of vacuolar sorting protein 34 and phosphoinositide 3-kinase, forming a complex which 
is the precursor to autophagosome formation [200].  
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To elucidate the potential mechanism of AMPK activation, further in vitro studies 
were performed. PG and MG increased ROS production, with PG causing elevated ROS 
levels at 1 mg/L. Significant increase of ROS with MG was achieved at 10 mg/L. 
Cellular proliferation of MCF10DCIS.com cells was decreased following 24 h exposure 
to either treatment but was reversed when cells were co-treated with glutathione. The 
ability of this antioxidant to attenuate the effects of the treatments provides additional 
support to the hypothesis that the generation of ROS caused by PG and MG is at least in 
part responsible for the anti-proliferative activities observed in DCIS breast cancer cells. 
Further investigation revealed that elevated levels of PG and MG increased cells halted 
in S phase which is frequently attributed to DNA strand breaks [201]. These breaks 
could result from oxidative base damage caused by either treatment [202]. PG at the 
same concentration also caused depolarization of the mitochondria, which is also 
associated with oxidative damage [203]. 
Determining a finite mechanism for a complex mixture of bioactive components 
is difficult due to multiple chemical structures involved, and for this reason, PG was of 
primary focus for the remaining mechanistic evaluation. An in silico modeling profile 
determined that pyrogallol has binding-specificity to the allosteric site of AMPK [204]. 
Similarly, AMP can activate AMPK in very low concentrations; as little as 2 µM caused 
half maximal activation of AMPK in a heart model [205]. When MCF10DCIS.com cells 
were transfected with AMPK siRNA, PG treatment was able to rescue both the mRNA 
levels along with total and phosphorylated protein levels. While these findings suggest 
that PG is acting through AMPK, they also demonstrate that PG increases constitutive 
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levels of AMPK through another mechanism (other than binding to the allosteric site) in 
addition to increasing the activation of AMPK. 
In summary, mango polyphenols and their major microbial metabolite pyrogallol 
may inhibit proliferation of DCIS breast cancer by upregulating of AMPK and 
downregulating of the AKT/mTOR pathway. To our knowledge, this was the first study 
that examined the activities of mango polyphenols and its GI derived metabolite 
pyrogallol in DCIS breast cancer progression. Results from this study support previously 
published work showing a downregulation of mTOR function from polyphenol exposure 
[206]. It seems that the impact on the AMPK-mTOR axis was in part induced by the 
generation of ROS and potentially by direct binding of PG to the allosteric binding site 
of AMPK causing its activation. Further investigations should be performed within 
physiological and pharmacological concentration levels to determine whether PG might 
advance cancer cells into autophagy. Because, basal levels of ROS are higher in cancer 
cells, allows for this prevention to be selective for cancer cells over non-cancerous cells. 
PG can cause increased ROS in cancer cells, disrupting the cellular balance and 
selectively advance these cells towards autophagy, while leaving non-cancerous cells 
unaffected. 
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CHAPTER IV 
ORAL EFFECTS OF PYROGALLOL IN 4 WEEK EXPOSURE IN ATHYMIC MICE 
WITH MCF10DCIS.COM XENOGRAPH TUMORS AND HDAC1 INHIBITION IN 
VITRO 
Introduction 
Pyrogallol is a metabolite formed in the GI tract following mango consumption.  
Certain bacteria strains, such as lactobacillus platarum, bacillus subtilis, and 
enterococcus faecalis, within intestine are able to produce tannase enzymes [207-209].  
These enzymes are produced as a defense mechanism in order to detoxify tannins, an 
anti-nutritional factor that binds proteins and forms indigestible complexes, which is 
detrimental to bacteria and other microbes [210] .  The enzymatic conversion of tannins 
to pyrogallol is summarized in Figure 27 below. 
Figure 27.  Conversion of tannins into pyrogallol following metabolism by L. 
platarum in colon. 
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Previous research revealed pyrogallol to have an anti-proliferative effect on DCIS 
proliferation in both in vitro and in vivo cancer models.  This proliferative effect was 
attributed to dysregulation of the mTOR pathway and activation of AMPK; however, it 
is plausible that these compounds cause epigenetic modifications as well. 
New investigations in polyphenol research have been centered on their ability to 
cause epigenetic modifications [211].  Epigenetics are alterations in gene expression 
which are not caused by changes to the DNA nucleotide sequences [212].  These 
modifications can occur through multiple mechanisms including DNA methylation, 
histone acetylation, and RNA interference [213].  Many disease conditions have been 
linked with epigenetic abnormalities including cancer, inflammation, and diabetes [214].  
Many publications have shown the epigenome to be a better target for therapeutics than 
genetic disorders because they are more readily reversible [215].   Two main groups of 
inhibitors have emerged as promising cancer therapeutics and include histone 
deacethylase (HDAC) and DNA methyl transferase inhibitors (DNMT) [216].  
Chromatin remodeling is a key characteristic in epigenetic regulation altering the 
chromosome to more open or closed conformation changes the accessibility to certain 
genes [217].  Histone acetyltransferases are a group of enzymes that are responsible for 
transferring acetyl groups to histones, more specifically their amino-terminal lysine 
residues, changing the chromatin architecture to a more open conformation, allowing 
space for regulator proteins to access DNA [218].  HDACs have the opposite effect and 
cause transcriptional repression by removing acetyl groups and decreasing the 
accessibility to DNA.   HDAC1 is overexpressed in multiple cancer types including 
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breast, gastric, colon, and prostate [219].  The knockdown of HDAC1 in vitro has shown 
retardation in tumor growth and an increase in apoptosis [220].  Targeting HDACs with 
inhibitors relieves transcription repression of genes critical for apoptosis and 
proliferative regulation [221]. 
Some of the concerns with current synthetic epigenetic drugs are the lack of 
specificity of these compounds, potentially leading to increased cancer progression, and 
their high levels of toxicity [222].  Polyphenol and polyphenol metabolites have been 
shown to be HDAC inhibitors in both precancerous and cancerous cells [223].  
The research performed here had 3 main objectives: 1) verify the reduction of 
MCF10DCIS.COM tumor volumes with two different pyrogallol concentrations, 2) 
determine if AMPK and mTOR genes are being affected by the pyrogallol treatment, and 
3) evaluate if pyrogallol is able to inhibit HDAC1.
Methods 
Cell Culture 
Human ductal carcinoma in situ breast cancer cell line MCF10DCIS.COM was 
obtained from Asterand, Inc. (Detroit, MI).  Cells were cultured in DMEM-F12 media as 
suggested by the vendor (Invitrogen, Carlsbad, CA) that was supplemented with 10% 
horse serum (Atlanta Biologicals, Lawrenceville, GA).  
Xenograft Study 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at Texas A&M University prior to their initiation.  Female athymic BALB/c 
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nude mice at approximately 3 weeks of age were ordered from Harlan Teklad (Houston, 
TX).  MCF10DCIS.COM cells (5X104 cells) were harvested and mixed with 50µL of 
Matrigel (BD Bioscience, San Jose, CA) and stored on ice until implantation.  Mice were 
implanted subcutaneously bilaterally into the mammary pad.  Tumors were allowed to 
grow 1 week prior to the initiation of dosing.  Animals were orally gavaged 100 µl daily 
with either ML at 0.2 mg/L or 0.8 mg/L of PG.  Control animals were dosed with a 
vehicle of citric acid buffer at a molarity of 0.2 and a pH of 3.5.  Tumors size and body 
weights were taken weekly and at time of necropsy.  Tumors and organs of interest were 
either saved via fixation in 10% formaldehyde or flash-frozen in liquid nitrogen. 
Analysis of mRNA Expression by Real-time PCR   
 Total RNA was isolated from tumor samples using mirVana miRNA Isolation kit 
(Applied Biosystems, Foster City, CA).   cDNA was synthesized from the isolated RNA 
with the use of a Reverse Transcription Kit (Invitrogen Corp., Grand Island, NY).  
Primers were designed using the Primer Express Software Version 3. (Applied 
Biosystems, Foster City, CA) and purchased from Integrated DNA Technologies Inc. 
(Coralville, IA).  qRT-PCR was conducted on an ABI Prism 7900 Sequence Detection 
System (Applied Biosystems, Foster City, CA) using SYBR Green PCR Master Mix 
(Applied Biosystems, Foster City, CA). 
HDAC1 Inhibition Assay 
 HDAC1 enzyme activity was performed with the HDAC Assay Kit (Cayman 
Chemical Company, Ann Arbor, MI).  MCF7DCIS.COM cells were seeded at a density 
of 5,000 per well in a 96 well black, clear bottomed plate and allowed to attach 
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overnight in 100 µL of media.  Cells were treated for 24 h with Trichostatin A at 2 µM 
(PC), butyrate at 100 µM, gallic acid at 10 and 20 mg/L, and pyrogallol at 10 and 20 
mg/L. The NC group was treated with at the same concentration vehicle as the treatment 
groups.  Following incubation, treatment media was aspirated and 200 µL of assay 
buffer and 10 µL of diluted HDAC substrate was added (kit constituents).  The plate was 
incubated for 3 h at 37ᵒC.  Following incubation cells were lysed in 50 µL lysis buffer 
and developer mixture (kit constituent) and incubated for an additional 15 min at 37ᵒC.  
Fluorescence was measure at an excitation wavelength of   340-360 nm and an emission 
wavelength of 440-465nm. 
 
Results 
Pyrogallol Effects on Tumor Volumes and Gene Expression on mTOR and AMPK 
Signaling 
 Following the 4 weeks of PG exposure both the low and high treatment groups 
had significantly reduced tumor volumes compared to controls from week 1 through 
necropsy (Figure 28).  For weeks 1-3 the tumor volumes in PG treated animals were 
approximately half that of the control treated animals.  Interestingly, the tumor volumes 
between the 0.2 mg/day treatment and the 0.8 mg/day PG did not differ through the 
duration of the study.  At the conclusion of the study all groups had similar body 
weights.  No significant differences were observed for liver weights.  Animals 
throughout the 4 week dosing duration never demonstrated any adverse effects to either 
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dose concentration.  The tumor growth and final volumes were very similar to the 
growth pattern and tumor volumes previously reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Effects of pyrogallol (PG) in athymic nude mice xenografted with 
MCF10DCIS.COM cells.   
Tumor volumes over four weeks were decreased by PG 0.2 mg/day and 0.8mg/day in 
athymic mice compared to vehicle treated controls (n=10 per group). *p < 0.05 
compared to the control (Dunnett’s test). 
 
 
 
any adverse effects to either dose concentration.  The tumor growth and final volumes 
were very similar to the growth pattern and tumor volumes previously reported. 
Gene Expression Profiles for mTOR and AMPK Pathways in Xenograph Tumor Tissue 
 Many genes along the mTOR and AMPK signaling axis were altered in tumor 
tissue in both the low and high PG treatment groups compared to (Figure 29A-B).  In 
respect to mTOR specific genes, AKT, PI3K, IGF1-R, and mTOR were all 
downregulated 60%, 52%, 68%, and 60%, respectively, for the low dose treatment and 
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79%, 47%, 61%, and 82%, respectively, for high dose treatment. AMPK genes had an 
inverse response and were upregulated in the PG treatment groups.  An activator of 
AMPK, Sestrin 2 was nearly 3 and 3.5 fold higher in the 0.2 mg/day and 0.8 mg/day 
treatments, respectively.  The LKβ1 levels were 1.6 fold higher than control in the high 
treatment group.  Beclin was increased 1.2 and 1.7 fold for the low and high dose 
treatments respectively.  AMPKα, AMPKβ, and the autophagy indicator LC3 were 
increased 1.6, 2.0, and 3.2 fold, respectively, in the low dose treatment and 1.8, 3.5, and 
4.8 fold, respectively, in the high dose treatment. 
Figure 29. Effects of pyrogallol (PG) on mRNA levels in tumors following four week 
oral exposure to 0.2 mg GAE/day (low) or 0.8 mg/day (high) PG in athymic nude 
mice xenografted with MCF10DCIS.COM cells.  
(A) mTOR signaling. (B) AMPK signaling. 
A 
B 
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HDAC1 Inhibition 
In vitro results of HDAC1 inhibition (Figure 30) indicate the significant 
inhibitory effect of pyrogallol at 20 mg/L during a 24 h exposure window in the DCIS 
breast cancer line.  The inhibition exerted by pyrogallol was about half as effective as the 
positive control, trichostatin A.  Butyrate has been reported to be an HDAC1 inhibitor 
[206], and the results observed for pyrogallol had a similar effect in inhibition.  Gallic 
acid had no effect on HDAC1 inhibition at both concentrations investigated. 
Figure 30. Effects of gallic acid and pyrogallol on HDAC1 activity compared to 
known inhibitors, trichostatin A (PC) and butyrate. NC is the non-treated controls. 
Discussion 
Oral treatment with pyrogallol in athymic mice for 4 weeks that had 
MCF10DCIS.com cell lines xenographed into their mammary pads produced a similar 
retardation in growth as our lab has previously reported.  Animals that received either 
treatment had tumor volumes that were half the volume of the control animals.  The 
*
*
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results here were not surprising, however, does add support for the anti-proliferative 
nature of the mango derived metabolite pyrogallol.  Treated tumors continue to grow 
throughout the course of the study, showing acceleration in growth after week three.  
This increased rate of proliferation could be attributed to the cancer developing 
resistance to the treatment, which is a common occurrence in cancer development [224]. 
A follow up study that compares genetic and protein expression at different time 
intervals, such as comparing expression levels at week 1 and week 5, may supply some 
insight to how this cancer is seemingly able to develop resistance to the pyrogallol 
treatment.  Previous reports have shown that polyphenols are able to induce drug 
metabolizing enzymes; therefore, it is plausible that continuous exposure to pyrogallol is 
resulting in the compound inducing its own metabolism [225]. 
 The gene expression results also coincided with previous findings and support 
the hypothesis that mTOR is being downregulated [226].  All mTOR genes investigated, 
IGF1-R, PI3K, AKT, and mTOR itself were all down regulated by more than 40% 
compared to controls.  A majority of the AMPK genes were upregulated by both 
treatments, with the exception of LKB1 in the low PG treatment group.  AMPK 
signaling can inhibit mTOR signaling when activated, however, mTOR can also inhibit 
AMPK depending on cellular conditions.  In the case of high nutrient levels, mTOR 
phosphorylates Ulk1 at Ser 757, which impedes Ulk1’s ability to bind with AMPK.  In 
low nutrient conditions AMPK activates ULK1 by phosphorylating Ser317 and Ser777 
in turn promoting autophagy. AMPK is also able to directly inhibit mTORC1 through 
interacting directly with TSC2 and Raptor.   
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Pyrogallol also had an effect on HDAC1.  HDAC1 is overly expressed in 
multiple cancer types, and leads to the repression of tumor suppressor genes. A natural 
compound that leads to HDAC1 inhibition would be advantageous because of their 
limited side effects compared to using synthetic small molecules. For the first time, a 
mango derived metabolite has been shown to inhibit HDAC1 in breast cancer.  
Interestingly, the precursor compound, gallic acid, did not have an effect.  These results 
provide further justification that the gut microbiota can promote or hinder disease 
advancement based upon the population and compounds produced. 
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 CHAPTER V 
BIOAVAILABILITY OF PYROGALLOL AND ITS MAJOR METABOLITES IN 
PLASMA, ANIMALS TUMORS, AND INTRACELLULARLY 
 
Introduction 
 Polyphenols are plentiful micronutrient present in the human diet that undergo 
the same fate similar to drugs once consumed, which includes absorption, distribution, 
metabolism and excretion (ADME) [227].  The body acknowledges polyphenols as 
xenobiotics, and therefore wants to eliminate them from the system through either phase 
1 or phase 2 metabolism or a combination of both [159, 228].  A majority of these 
metabolizing enzymes can be found in the liver, small intestine, and kidney and have a 
primary responsibility for detoxifying harmful foreign compounds [229]. A summary of 
this conversion is illustrated in Figure 31 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. ADME diagram following mango consumption. 
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Initially, polyphenols must separate from the food matrix in order for metabolism 
and distribution to occur.  Many factors contribute the bioaccessabilty of polyphenols 
and include the presence of glycosides and acylation’s, solubility, and interconnectivity 
with the food matrix [230].  Tannins included a large group of polyphenols which are 
considered to have poor bioavailability because of their ability to polymerize and their 
protein binding affinity [231].  Another factor that limits polyphenol bioavailability is 
their hydrophilicity, making it difficult for them to cross the phospholipid membrane and 
enter cells [232].  Polyphenols also commonly undergo glycolsylation which increases 
their affinity for water, and studies have shown that flavonoids that undergo 
deglycosylation, primarily through the enzyme lactase phoridzin hydrolase (LPH), are 
more readily absorbed [233]. LPH resided on the luminal service of enterocytes, with 
cleaves aglycone and allows for flavonoids to be absorbed supposedly through passive 
diffusion [234].  Lower molecular weight polyphenols have been shown to be 
transported into cell cells via different transporters, such as monocarboxylic acid 
transporter and other active transporters that are responsible for the uptake of lactate, 
pyruvate, and ketone bodies [235, 236]. 
The goal of this chapter was to examine the bioavailability of pyrogallol both in 
vivo and in vitro in MCF710DCIS.COM breast cancer cells.  Tumors collected from 
xenographed mice treated with pyrogallol for 4 weeks will be analyzed for pyrogallol or 
pyrogallol derived metabolites.  Plasma collected at time of necropsy was also analyzed 
for these compounds. In vitro the same cell line will be used and treated with pyrogallol 
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to determine if this compound is able to enter a cell and what metabolism occurs at the 
cellular level.  It is hypothesized that pyrogallol will not bio-accumulate in the tumor 
tissue due to their polarity, however, the parent compound or metabolites are expected to 
be in the plasma.  Due to the low molecular weight, 126.1 g/mol, of pyrogallol it is 
expected in to be found intracellularly but is expected to be metabolized quickly. 
Methods 
Cell Culture 
Human ductal carcinoma in situ breast cancer cell line MCF10DCIS.COM was 
obtained from Asterand, Inc. (Detroit, MI).  Cells were cultured in DMEM-F12 media as 
suggested by the vendor (Invitrogen, Carlsbad, CA) that was supplemented with 10% 
horse serum (Atlanta Biologicals, Lawrenceville, GA).  
Xenograft Study 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at Texas A&M University prior to their initiation.  Female athymic BALB/c 
nude mice at approximately 3 weeks of age were ordered from Harlan Teklad (Houston, 
TX).  MCF10DCIS.COM cells (5X104 cells) were harvested and mixed with 50 µL of
Matrigel (BD Bioscience, San Jose, CA) and stored on ice until implantation.  Mice were 
implanted subcutaneously bilaterally into the mammary pad.  Tumors were allowed to 
grow 1 week prior to the initiation of dosing.  Animals were orally gavaged 100 µl daily 
with either PG at 0.2 mg/L  or 0.8 mg/L.  Control animals were dosed with a vehicle of 
citric acid buffer at a molarity of 0.2 and a pH of 3.5.  Tumors size and body weights 
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were taken weekly and at time of necropsy.  Tumors and organs of interest were either 
saved via  fixation in 10% formaldehyde or flash-frozen in liquid nitrogen. 
Bioavailability in Tumor Tissue, Plasma, and In Vitro 
For analysis of pyrogallol metabolites in plasma, 500 µl of mice plasma was 
acidified with 25 µl of 88% formic acid. 75 µl of 10% SDS was then added followed by 
325 µl of 0.1 % formic acid MeOH. After proteins were denatured, 50 µl of 3 M KCl 
was added to remove any residual SDS. Samples were sonicated for 10 min and 
centrifuged at 12,000 RPM for 5 min at 4oC. Supernatants were filtered through a 0.45
um filter prior to LC-MS analysis. 
Methodology for analysis of pyrogallol metabolites in tumors was based off of 
method by Margalef et al [202]. Briefly, mice tumor tissue was homogenized and 
incubated with 50 µl of 10% SDS. This was followed with two independent extractions 
of homogenized tissue with 400 µl of 0.1% formic acid acetonitrile. Samples were 
centrifuged at 12,000 RPM for 5 min at 4oC, and supernatants were evaporated under
vacuum using a ThermoFisher Speed Vac. Dried samples were brought up in 200 µl of 
1:1 0.1% MeOH:H20, and analyzed on LC-MS. 
MCF10DCIS.COM cells were grown in 10 cm cell culture dishes and allowed to 
grow to 100% confluency.  Media was aspirated, and treatment media was added to each 
dish.  Treatment duration was 1 or 2 h.  At the end of treatment, media was aspirated out 
of each dish and each dish was wash twice with PBS to ensure removal on any 
extracellular polyphenols.  Cells were scraped from their dishes with 2mL acidified 
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methanol.  Cells were transferred to a 1.7 mL microcentrifuge tube and lysed with a 
syringe.  Samples were stored at -80°C until analysis could be performed. 
Results 
Pyrogallol Characterization and Detection in Plasma and Tumor Tissue 
Following the 4 week exposure window of the PG treatment both tumor tissue 
and plasma were analyzed via HPLC-MS in order to determine if PG and its metabolites 
were absorbed and metabolized. No PG or PG metabolites were found to bioaccumulate 
in tumor tissues.  In contrast, pooled plasma extracts show the presence of the PG 
derived metabolite pyrogalloyl-O-sulfate with a peak at 205.2 m/z and shown in Figures 
32A-B.  This result demonstrates pyrogallol was absorbed and metabolized. 
Pyrogallol Characterization and Detection in MCF10DCIS.COM Cells 
Breast cancer cells that were incubated in a treatment media of pyrogallol at 20 
and 50 mg/L had both pyrogallol and the metabolite methyl-pyrogallol-sulfate present 
intracellularly after 1 hour.  When cells were treated at 20 mg/L approximately 0.36% of 
pyrogallol was absorbed and 0.74% methyl-pyrogallol-sulfate was either absorbed or 
formed intracellularly.  When the dose was increased to 50 mg/L 0.716% of the 
pyrogallol was absorbed and 0.2% of the methyl-pyrogallol-sulfate was present.  This 
data set is displayed in Figure 34. 
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Discussion 
 Pyrogalloyl-O-sulfate was found in mouse plasma in animals that received orally 
administer pyrogallol for 4 weeks.  No parent compound was found in either plasma or 
in the tumor tissue itself.  It can be concluded that oral administration of pyrogallol leads 
to rapid metabolism, presumably in the liver, following exposure.  The sulfation of 
polyphenols has been noted with other phenolic compounds such as gallic acid, catechol, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. A. Extracted Ion Chromatogram of pyrogallol-O-sulfate at 205 m/z in 
mouse plasma following 0.8 mg dose of pyrogallol B. Mass spectrum for pyrogallol 
sulfate present in mouse plasma. 
 
A 
B 
B 
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Figure 33. Percentage of pyrogallol and methyl-pyrogallol-sulfate intracellularly 
absorbed in MCF10DCIS.COM cells following 1 hour of exposure to 20 and 50 
mg/L pyrogallol. 
and resorcinol and is no surprise that pyrogallol undergoes a similar metabolism [85, 
237, 238].  Sulfotransferases (SULTs) are a group of enzymes found in a variety of 
tissues and are responsible for the sulfonation of xenobiotics and endogenous 
compounds [239]. 3’phosphoadenosine 5’ phosphosulfate (PAPS) is responsible for 
donating the SO3- group being transferred by SULTs [240]. The addition of a sulfonate
moiety normally increases a compounds polarity making them more water soluble and 
decreases their reactivity.  This is not true for all compounds, and in some instances the 
addition of this functional group forms reactive electrophiles [241241]. Figure 35 
summarizes the sulfation and methylation of pyrogallol. 
The lack of pyrogallol, or pyrogallol metabolites in tumor tissue was expected 
due to their polarity.  This finding suggests that these compounds are exuding a systemic 
effect on tumor proliferation instead of eliciting an effect intracellularly.  In a follow up 
20mg/L   50mg/L 
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Figure 34. The sulfation and methylation of pyrogallol to produce metabolites 
found in plasma and intracellularly.  
experiment would be interesting the monitor the sulfation of pyrogallol through the 
course of the study.  It is possible that the mice are becoming more efficient at clearing 
these compounds and consequently could be the reason we saw more aggressive growth 
in the treatment animals in the final week. 
The work performed in vitro had a paradoxical effect to the in vivo analysis 
because both pyrogallol and methyl-pyrogallol-sulfate were found directly within the 
cancer cells.  Pyrogallol was present in the first hour, but had been completely 
metabolized to methyl-pyrogallol-sulfate by the second hour.  This rapid conversion of 
pyrogallol was similar to what was reported in vivo. When the concentration of 
pyrogallol was increased to 50 mg/L there was an increase in pyrogallol concentration 
and a decrease in the metabolite concentration.  This indicated that the 
sulfation/methylation is rate limiting once the system is saturated with pyrogallol. 
In conclusion, pyrogallol is a rapidly sulfated polyphenol with the ability to 
transcend the phospholipid membrane to enter cancer cells.  Further investigation should 
focus on the metabolites and determine if they have any bioactive properties.  The 
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sulfated metabolite instead of the parent compounds, at least in vivo, was the only 
pyrogallol derivative present in plasma, and therefore the only compound bioavailable to 
elicit an effect.  It would be interesting to investigate in a future study if changing the 
method of delivery from oral to either intraperitoneal or intravenous injection could 
increase pyrogallol concentration in tumor tissue.  
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CHAPTER VI  
CONCLUSION AND FUTURE STUDIES 
  
 This research focused on the antiproliferative activities of mango polyphenols 
and their central microbial metabolite pyrogallol in ductal carcinoma in situ stage model 
of breast cancer. Previous studies have demonstrated the cancer-cytotoxic activities of 
many polyphenols but their microbial metabolites have only infrequently been 
investigated. Increased consumption of polyphenols has been linked to a decreased 
incidence in chronic diseases.  Epidemiological studies and meta-analyses have 
correlated the intake of polyphenols from fruits and vegetables, teas and spices to the 
incidence of chronic disease, but only some show a significant inverse correlation to 
certain types of chronic diseases.  Factors that are responsible for the high variability in 
human clinical and epidemiological studies include other nutritional factors such as 
intake of carcinogens (e.g.  polycyclic aromatic  hydrocarbons), overall lifestyle, phase I 
and phase II metabolism, microbial metabolism of polyphenols and other factors. Upon 
ingestion, polyphenols are rapidly metabolized by host and microbial enzymes that are 
characterized by significant inter-individual differences.  Few studies have been 
performed with microbial metabolites of polyphenols. Pyrogallol is a central metabolite 
of dietary tannins that occur in most fruits, vegetables, teas and spices.  
 Several studies investigated polyphenol effects on breast cancer, where the 
information on polyphenol efficacy on DCIS breast cancer is very limited.  DCIS 
research is important because is a unique form of breast cancer that captures a late, pre-
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invasive stage.  In the initial study of this dissertation, in vitro assessment of a mango 
extract that is low in tannins but rich in small phenolic acids, pyrogallol, gallic acid, and 
methyl gallate were investigated.  Additionally, potential synergistic activities with 5-FU 
were assessed. The concentration (10 mg/L) was selected for a majority of the work due 
to reproducible effects without cytotoxicity non-cancerous cell lines.  A limitation of this 
concentration is that some of the cellular mechanisms were not as clearly identified as 
might have been at higher concentrations.  While this dose is similar to what is 
achievable through diet, it has its limitation for mechanistic evaluations.  A higher dose 
may have elicited a more pronounced mechanistic response in the selected models. Yet, a 
clinical systemic exposure to this higher level might yield similar cytotoxic side-effects 
as they are experienced with conventional chemotherapy.  
Pyrogallol was selected as central study treatment for the following reasons: a) 
pyrogallol is the main central metabolite of microbial metabolism of tannins that occur 
in mango, most fruits, vegetables, teas and spices, b) it had the greatest antiproliferative 
effect of any individual polyphenol screened and reduced DCIS proliferation by more 
than 50%.  Following compound selection, concentration-dependency of cytotoxic 
activities were investigated in both cancerous and non-cancerous breast cell lines.  A 
dose range of 10 mg/L-20 mg/L of pyrogallol was not cytotoxic in non-cancer cells but 
caused significant anti-proliferative activities in cancer cells. 
Initially, it was hypothesized that pyrogallol or the polyphenolic extract may 
have a synergistic effect with the cancer drug, 5-FU, based on previously published work 
with other polyphenols.  5-FU was also included as a positive control in vitro and in the 
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initial animal study.  Non-significant interactions were noticed between 5-FU and the 
polyphenol-based treatments.  5-FU is a genotoxic compound whose main mechanism of 
action is being misincorporated into macrostructures such as DNA and RNA resulting in 
inhibition of DNA replication and problems in protein translation.  The dysregulation in 
protein production eventually leads to cell death, and this treatment is not targeted to 
only affect cancer cells, but also affects normal cells resulting in unwanted side effects.  
It was hypothesized that there would be an additive or synergistic interaction between 
the polyphenol treatment and 5-FU, because a major mechanism of polyphenol-induced 
suppression of proliferation seemed to be based on interactions with the mTOR pathway.  
The differences in mechanism were hypothesized to produce at least additive effects 
when they were co-administered; however, at the concentration used, no interactions 
with 5-FU were detected. 
Based on its central role in inflammation and proliferation, the mTOR pathway 
was selected as the primary pathway of investigation.  PG had a more pronounced effect 
on mRNA levels, and reduced IGF1-R, P13K, HIFα, AKT, and mTOR. ML reduced 
PI3K, AKT, and mTOR mRNA levels compared to non-treated controls.  Both 
treatments reduced protein expression of IGF1-R, IRS1, IF, AKT, and P70S6.  PG also 
reduced total mTOR levels.  Both treatments also had an effect on phosphorylated 
protein levels, with PG significantly reducing IGF1-R, AKT, and P70S6 levels. ML had 
a similar effect and significantly decreased IR, AKT, and P70S6 phosphorylation levels.  
The main conclusion elucidated was the PI3k/AKT/mTOR signaling axis appears to be 
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at least in part cause for decreased proliferation induced by dietary-relevant 
concentrations of ML and PG. 
This initial cell based assays concluded that mango polyphenols had an effect on 
DCIS breast cancer, and therefore supplied justification for further investigation.  A 
xenograph model was employed because it was deemed a suitable model to further 
examine the anti-proliferative activities of the selected polyphenol-treatments in breast 
cancer development.  DCIS cells were xenographed into the mammary pads of female 
athymic mice, and treated for 4 weeks with either a mango extract or pyrogallol at 0.8 
and 0.2 mg/d by oral gavage. Treatments significantly reduced tumor volumes compared 
to vehicle treated controls.  Treated animals did not display any signs of toxicity and had 
similar body and liver weights compared to controls. 
Tumor-tissue was the main focus for a majority of the molecular work and much 
of what was discovered from the in vitro exploration was confirmed in the tumor tissue.  
Major genes along the mTOR pathway was significantly reduced, greater than 40% for 
both treatments, and included IRS1, IGF1-R, PI3K, AKT, ERK, and mTOR.  Results 
also support the in vitro findings that polyphenols have anti-inflammatory properties and 
reduced CRP and TNFα with MG treatment and IL-1β in PG treated tumors. Total 
protein levels for IRS1, AKT, and mTOR were reduced more than 20% in polyphenol 
administered tumors.  A downregulation in protein phosphorylation was also noted with 
MG including IR, IRS1, IGF1-R, and mTOR phosphorylation. PG treatment had a 
similar effect; however, p-mTOR was not significantly reduced.  Further, p70S6K, an 
indicator of mTOR activity was reduced along with p-ERK.  Currently mTORC1 is 
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known to have 4 phosphorylation sites (S1261, T2446, S2448, and S2481), but the 
activity of each of those sites has not been characterized completely.  In this instance it 
may have been more advantageous to examine each of the phosphorylation sites instead 
of just one in order to better elucidate the effect PG had on p-mTOR. 
While the effects to the mTOR signaling axis explain the anti-proliferative 
activities of polyphenols both in vitro and in vivo, it was hypothesized that potentially 
other mechanism affecting mTOR could be involved.  A further exploration in vitro 
revealed that both treatments acted as ROS generators in DCIS breast cancer cells.  This 
led to the hypothesis that possibly AMPK, a pathway induced by ROS might be involved 
in the inhibition of the mTOR pathway.  AMPK, a kinase involved in cellular energy 
homeostasis, can be causally involved in the inhibition of mTOR upon activation.  
Western blot results indicate that AMPK pathway constituents including Sestrin, 
Becklin, LKB1, and ULK were upregulated in tumor samples.  Polyphenol treatments 
induced phosphorylation of AMPKα at Thr 172 which is found on the catalytic subunit. 
Overall, the activation of AMPK through phosphorylation at Thr 172 caused a reduction 
in mTOR and consequently downregulated proliferation in DCIS cancer cells.  Further 
analysis in silico revealed PG ability to directly bind with the allosteric binding site of 
AMPKα which would result in its activation.  Consequently PG may activate AMPK 
either through ROS generation, or through direct allosteric activation. 
A follow-up in vivo study was performed in order to compare a higher dose PG 
treatment of 0.8 mg/day to the previously used dose of 0.2 mg/day.  The major objectives 
were: 1) to further investigate the anti-proliferative mechanisms at two different 
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concentrations with the hypothesis that the higher dose of PG would induce autophagy 
through the activation of AMPK, while the lower dose mainly reduced proliferation.  2) 
To evaluate the bioavailability of pyrogallol and determine if it was reaching the site of 
action or if the anti-proliferative activities might have been induced systemically.  
Anti-proliferative activities of PG were comparable to findings from the previous 
study with treatments animals having reduced tumor volumes for the duration of the 
study.  The tumors of the treatment animals continued to grow throughout the treatment, 
but at a less rapid pace than control tumors.  There was no significant difference in 
tumor volumes between the two different PG concentrations.  This is advantageous, 
because a reduced dose that is more realistically achievable had the same effect as an 
elevated dose which could be less achievable through diet or supplementation.   
Genes along both the AMPK and mTOR pathways were significantly decreased 
in PG treated tumors, and mirrored the results previously described adding additional 
support that these are the major pathway being affected by PG.  Both tumor and plasma 
samples collected at time of necropsy were analyzed for the presents of PG and PG 
metabolites.  The tumors did not contain any measurable concentrations of PG or 
metabolites commonly found systemically.   Pyrogallol sulfate was detected and 
characterized in the plasma samples.  This may suggest that the observed anti-
proliferative activities may be due to either extracellular or systemic activities.  The PG-
sulfated metabolite present in the plasma samples indicated that PG is sulfated rapidly, 
presumable through SULTs in the liver. This is consistent with currently ongoing human 
clinical studies focusing on the bioavailability of PG following 400 grams of mango 
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consumption. Cell culture analysis of samples treated with PG indicated that both PG 
and methylated PG were present intracellularly at an absorption rate of 0.3 and 0.7% at 
20 mg/L for 1 h.  Potential follow up research should focus on PG metabolites, both the 
sulfate and methylated forms and determine if they have an effect in DCIS cancer.  
Another interesting observation from the xenograph model is that the treatments 
only slowed the tumor development.  Instead, the difference in tumor-size between 
controls and treatment was decreasing after the initial treatment phase over the duration 
of the study.  Since pyrogallol is rapidly metabolized and detoxified by SULTs and 
SULTs are present in multiple tissue types, it is plausible that sustained exposure to PG 
increased the detoxifying activity of SULTs through upregulation of SULTs expression, 
causing a more rapid excretion of pyrogallol metabolites. 
In conclusion, the research presented within has shown polyphenols associated 
with mango consumption delayed proliferation in DCIS breast cancer both in vitro and 
in vivo.  Further research needs to be conducted to determine if these results translate to 
an effect in humans at a dose achievable through either dietary intake or through dietary 
supplementation. 
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